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autoimmune disorders such as paraneoplastic syndrome,  multiple 
sclerosis (MS), and systemic lupus erythematosus (Bhat and 
Steinman, 2009).
Despite the dogma that peripheral immune responses could 
not affect CNS function under normal circumstances, substantial 
evidence over the past 10 years suggests that immune-CNS cross-
talk may be the norm rather than the exception. An intriguing 
example supporting this new idea comes from studies of immune-
deficient (severe combined immunodeficient, SCID) mice. These 
mice, which lack peripheral T-cells, show impairments in the 
acquisition of cognitive tasks. Repopulating their T cells via bone 
marrow transfer significantly restores their adaptive immunity and 
improves learning. Similarly, acute depletion of adaptive immunity 
in normal adult mice impairs their learning behavior (Brynskikh 
et al., 2008). Thus, peripheral immune cells can alter cognition 
in the absence of CNS immune cell infiltration, suggesting that 
neural–immune cross-talk may involve more than the simple 
“breaching” of the BBB.
Moreover, breaching of the BBB may not always be harmful. 
In traumatic and ischemic injury, MS, infection, and neurode-
generative diseases, activation of an immune response in the CNS 
may instead contribute to the maintenance, functional integrity, 
and repair of tissue following an insult (Graber and Dhib-Jalbut, 
2009). Furthermore, new therapies for neurodegenerative disor-
ders, including administration of the cytokine interferon-beta 
(IFN-β) and intravenous immunoglobulin, enhance the protec-
tive and regenerative aspects of the immune system in the CNS 
(Sozzani et al., 2010). A better understanding of both the neuro-
protective and destructive roles of the immune response within 
IntroductIon
Although the brain has classically been considered “immune-
privileged”, current research suggests that there is extensive com-
munication between the nervous and the immune systems in 
both health and disease (Carson et al., 2006; McAllister and van 
de Water, 2009). The primary goal of this review is to discuss 
recent evidence that a large number of “immune” proteins are 
expressed in the central nervous system (CNS) where they play 
critical modulatory roles in activity-dependent refinement of con-
nections, synaptic transmission, synaptic plasticity, and homeosta-
sis during brain development. These roles for immune molecules 
during neural development suggest that they could also mediate 
pathological responses to chronic elevations of cytokines in neu-
rodevelopmental disorders, including autism spectrum disorders 
(ASD) and schizophrenia.
Ever since the 1900s when bacteriologists Ehrlich, Goldman, 
and Lewandowsky injected dye into animals and noted that the 
dye stained all of the organs except for the brain, the concept that 
the brain is compartmentalized from the rest of the body by the 
“blood–brain barrier” (BBB) has persisted. Until recently, immune 
cells were thought to infiltrate the CNS only in rare times of disease 
or trauma (Maehlen et al., 1989; Amantea et al., 2009). Under 
these circumstances, glial cells in the brain produce cytokines that 
cross the BBB and signal recruitment of blood-derived monocytes 
which migrate back through the compromised BBB into the CNS 
and aid microglia in causing neural inflammation, degeneration, 
and cell death (Janeway et al., 2005; Bauer et al., 2007). The effects 
of immune cell infiltration into the CNS has historically been 
documented as mostly detrimental, especially in the  context of 
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the CNS is thus essential for continuing to improve treatments. It 
is  increasingly clear that immune molecules should not be blocked 
entirely from interaction with the brain, but rather that the inter-
play between the nervous and immune systems retain balance in 
order to promote health.
Numerous recent studies (many of which will be centrally 
addressed in this review) have brought attention to important roles 
for immune molecules in the nervous system. In the absence of 
disease, many types of immune molecules are normally expressed 
in the healthy brain and are essential for brain development 
(Boulanger, 2009; Carpentier and Palmer, 2009; Deverman and 
Patterson, 2009). Multiple members of the large family of cytokines 
are normally produced in the healthy brain where they play criti-
cal roles in almost every aspect of neural development, including 
neurogenesis, migration, differentiation, synapse formation, plas-
ticity, and responses to injury (Boulanger, 2009; Carpentier and 
Palmer, 2009; Deverman and Patterson, 2009). In addition, other 
immune molecules from both the innate and adaptive immune 
systems, including major histocompatibility complex (MHC) I 
molecules, putative MHCI receptors, and components of the com-
plement cascade have recently been found in the healthy brain 
during development. These immune molecules play critical roles in 
synapse refinement and plasticity in the cortex, hippocampus and 
cerebellum, in information processing in the olfactory system, and 
in potentially mediating the effects of cytokine infiltration during 
disease (Boulanger, 2009; Shatz, 2009).
Despite these recent advances, most of the details of when, 
where, and how immune molecules function in the CNS remain 
unknown. Moreover, it is unclear if these molecules behave similarly 
in the CNS as they do in the immune system. Do these molecules 
have completely novel functions in the CNS or can we deduce 
their mechanism from their role in the immune system? In order 
to understand this burgeoning concept of “immune” proteins as 
key players in brain development and function, it is necessary first 
to have a basic understanding of their already extensively stud-
ied roles in the immune response. For this purpose we will begin 
this review with an overview of the basic concepts of the immune 
response, focusing on the immunological roles of a limited number 
of molecules, including MHCI, cytokines, and complement, whose 
novel roles in the nervous system will be discussed in later sections. 
This introduction to the immune system will be followed by sec-
tions detailing the localization of immune molecules in the CNS, 
as well as their roles in refinement of connections, synaptic trans-
mission, plasticity, and homeostatic synaptic scaling. The intent 
of this review is to highlight the importance of this exciting new 
research area, underscoring the importance of immune molecules 
in development and function of connections during brain develop-
ment and disease.
the Immune response
The immune system, like the nervous system, is highly complex and 
comprised of specialized components that are fundamental to the 
existence of an individual. Humans are constantly bombarded with 
infectious organisms and invading pathogens. Fortunately, we have 
evolved a highly ordered defense – the immune system. Many details 
of how the immune response works have been elucidated, but an 
extensive overview of the immune system is not the purpose of this 
review. Instead, we seek here only to draw a basic outline of what is 
known about specific molecules of interest to neuroscientists and 
the roles of these molecules in immunity.
Vertebrate immunity is composed of two complementary 
branches: an innate and an adaptive system (Figure 1; Janeway 
et al., 2005). Innate immunity produces a rapid response to evolu-
tionarily conserved pathogens and serves as the first line of defense 
in the immune system. Cells with important roles in the innate 
immune system include macrophages, dendritic cells and natu-
ral killer (NK) cells. If an antigen gets past the innate immune 
system, it is attacked and destroyed by components of the adap-
tive immune response composed of highly specialized lymphoid 
cells, called B and T-lymphocytes, and antigen-specific antibodies 
that help eliminate pathogens (Janeway et al., 2005). The adaptive 
response is defined by its ability to recognize and remember specific 
pathogens and thus mount stronger and more rapid responses upon 
subsequent exposures to the same pathogen. The adaptive response 
is dependent upon the innate response. Helping to bridge this con-
nection are certain proteins common to both pathways including 
those of the complement system as well as signaling molecules 
called cytokines that play key roles in the initial innate immune 
response and the subsequent adaptive response (Rothman et al., 
1990; Janeway et al., 2005).
cytokInes
The ability to convey information is fundamental to an effective 
immune system, making signaling molecules of paramount impor-
tance. Cytokines are one of the largest and most diverse families of 
signaling molecules in the body. Under healthy conditions, most 
cytokines circulate at very low concentrations but can increase up 
to 1,000-fold during trauma or infection (Janeway et al., 2005). 
Released early in the immune response, they cause a myriad of out-
comes including increased MHCI expression and secretion of addi-
tional cytokines which augment inflammatory responses (Linda 
et al., 1998). Cytokines bind to specific membrane receptors, which 
then signal via second messengers eventually resulting in alterations 
in gene transcription. There are more than 50 known cytokines, 
often classified into pro-and anti-inflammatory families. The major 
pro-inflammatory cytokines responsible for early responses are 
IL1-α, IL1-β, IL-6, and TNF-α. Other pro-inflammatory mediators 
include LIF, IFN-γ, OSM, CNTF, TGF-β, GM-CSF, IL11, IL12, IL17, 
IL18, and a variety of chemokines such as IL-8, CCL2 (MCP-1), 
CCL5 (RANTES), and CX3CL1 (Fractalkine) that chemoattract 
inflammatory cells. Anti-inflammatory cytokines limit the poten-
tially detrimental effects of sustained or excess inflammatory 
reactions. The major anti-inflammatory cytokines include the 
interleukin (IL)-1 receptor antagonist (IL1-ra), IL-4, IL-6, IL-10, 
IL-11, IL-13, and TGF-β. With the possible exception of IL-1ra, 
all of these anti-inflammatory cytokines have at least some pro-
inflammatory properties (Janeway et al., 2005). A highly dynamic 
balance exists between pro- and anti-inflammatory cytokines and 
this signaling can result in diverse outcomes, such as increased or 
decreased expression of membrane proteins, proliferation, and/or 
secretion of effector molecules. In fact, it is often difficult to make 
generalizations about the roles of individual cytokines due to their 
frequently redundant and pleiotropic effects. To add to this com-
plexity, combinations of cytokines can act either synergistically or 
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In this review, we will focus mostly on three cytokines that 
have been extensively studied in the nervous system – tumor 
necrosis factor (TNF), interleukin (IL)-1, and IL-6. Deregulated 
antagonistically depending on the state of the target cells and the 
combinations, doses, and temporal sequence of cytokine secretion 
(Janeway et al., 2005).
Injury or
infectionINNATE
T
ADAPTIVE
Blood vessel
Tissue
1.
2.
4.
5.
3.
NK
7.
6.
9.
10.
8.
T
To the lym
ph node TB
BB
B T
T
TH
T
11.
Clonal
expansion
To periphery
Figure 1 | innate and adaptive immunity. A simplified schematic of the two 
branches of the immune response. Following injury or infection, pathogens 
(bacteria, virus or foreign protein) infiltrate tissue. The innate response provides 
immediate defense against infection (1–5): 1. Neutrophils engulf the pathogen 
and destroy it by releasing antimicrobial toxins. 2. Macrophages can directly 
phagocytose pathogens, leading to production of cytokines and recruitment of 
more cells from the blood. 3. Infected cells displaying low levels of MHCI on 
their surface are directly detected by natural killer (NK) cells, which release lytic 
enzymes causing the infected cell to die via apoptosis. 4. Bacteria can also be 
recognized by the complement system, resulting in their lysis. 5. Macrophages 
and dendritic cells can become antigen presenting cells (APCs) by taking up 
peripheral antigens and migrating to lymph nodes to present antigen on their 
surface to naïve B- and T- cells. The adaptive response confers the ability to 
recognize and remember specific pathogens to generate immunity (6–11): 6. 
APC interaction with B- and T- cells in the lymph nodes leads to B- and T-cell 
activation and migration to the periphery where they mediate adaptive 
immunity. 7. Once activated, the T-cell undergoes a process of clonal expansion 
in which it divides rapidly to produce multiple identical effector cells. Activated 
T-cells then travel to the periphery in search of infected cells displaying cognate 
antigen/MHCI complex. 8. Peripheral APCs induce helper T cells to release 
cytokines and recruit cytotoxic T cells (CTL). 9. Activated antigen-specific B cells 
receiving signals from helper T-cells differentiate into plasma cells and secrete 
antibodies. 10. Antibodies bind to target antigens forming immune complexes 
which can then activate complement or be taken up by macrophages through Fc 
receptors 11. Formation of cytotoxic T-cell synapses causes lysis of the 
infected cell.
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is established during development through the creation of millions 
of T-cells, each harboring a unique TCR. When a TCR binds to an 
MHC  molecule presenting a non-self peptide, an immunological 
synapse is formed (Figure 2A). The immune synapse consists of 
the TCR (αβ subunits) bound by a cluster of differentiation protein 
3 complex (CD3) and ζ-chain (CD3ζ) proteins. In mammals, the 
CD3 complex contains a CD3γ chain, a CD3δ chain, and two CD3ε 
chains. The CD3γ, CD3δ, and CD3ε chains are highly related cell-
surface proteins of the immunoglobulin superfamily containing 
a single extracellular immunoglobulin domain. Formation of the 
complete T-cell immune synapse initiates an immune response, 
leading to eventual lysis of cells displaying foreign peptide (Cantrell, 
1996; Abbas et al., 2000).
In addition to binding T-cell receptors, MHCI molecules also 
bind to inhibitory receptors (IRs) on natural killer (NK) cells, which 
are part of the innate immune system (Krzewski and Strominger, 
2008; Long, 2008). There are three major families of MHCI recep-
tors found on NK cells including killer cell-immunoglobulin 
receptor (KIR), CD94/NKG2 and leukocyte immunoglobulin-
like receptor (LILR) in humans and LY49, murine NKG2 and the 
paired immunoglobulin-like receptor (PIR) receptors in rodents. 
Each family has multiple members that can either inhibit or acti-
vate apoptosis of a target cell. The balance between activating and 
inhibitory receptor (IR) signaling on the NK–target cell interface 
determines the outcome of the interaction. A lack of MHCI on the 
target cell, caused by viral infection or tumorigenesis, favors forma-
tion of the activating immune synapse (Figure 2B). Conversely, the 
presence of MHCI on the target cell results in binding of MHCI 
to NK-IRs, which initiate a classical NK-IR signaling pathway that 
prevents the formation of immune synapses required for NK acti-
vation and apoptosis of the target cell (Krzewski and Strominger, 
2008; Long, 2008).
the complement system
The complement system is a critical component of both innate and 
adaptive immunity. Although the complement system is most com-
monly classified under innate immunity, this process is also induced 
by antibodies, constituents of adaptive immunity, to more rapidly 
mark pathogens for destruction (Janeway et al., 2005). Activation 
of complement initiates a complex biochemical activation cascade 
of over 25 proteins and protein fragments that opsonize pathogens 
and induce inflammatory responses. It consists of three distinct 
pathways – the classical, the mannose binding lectin (MBL), and 
the alternative pathways, that all depend on different molecules for 
their initiation but converge on the C3-convertase and result in the 
same cascade of complement activation. The classical pathway is 
triggered by activation of the C1 complex (C1q, two C1r, and two 
C1s molecules thus forming C1qr2s2), which occurs when C1q binds 
to antibody: antigen complexes or when C1q binds directly to the 
surface of a pathogen. Binding leads to conformational changes 
in the C1q molecule, in turn leading to the activation of comple-
ment proteases that cleave specific proteins to release cytokines 
and initiate a cascade of further cleavages, resulting in amplifica-
tion of the response and activation of the cell-killing membrane 
attack complex. C3-convertase cleaves and activates component 
C3, creating C3a and C3b and causes a cascade of further cleavage 
and activation events. Activation of the complement cascade leads 
to lysis of the target cell.
 overproduction of these three pro-inflammatory cytokines as 
well as the resultant disequilibrium between pro-inflammatory 
and anti-inflammatory functions, have been shown to underlie 
the pathophysiology of many diseases such as autoimmune dis-
eases, therefore these cytokines are attractive candidates for central 
signaling roles (Hawkes et al., 1999; Cunningham et al., 1996). All 
three of these cytokines are involved in the acute immune response 
and initial inflammation. They are produced by many cell types 
including macrophages, monocytes, fibroblasts, dendritic cells, T 
cells, B cells, monocytes, fibroblasts, and endothelial cells. Among 
one of the first cytokines discovered, IL-1 (α and β) is most potent 
at activating fever. IL-6 was originally identified as a T-cell-derived 
factor that induces activated B cells to differentiate into antibody-
producing cells (Figure 1). TNFα is well known for its ability to 
induce inflammation, inhibit tumorigenesis and viral replication, 
and to induce apoptotic cell death. Although these three cytokines 
are associated with the acute response in innate immunity, they 
also act to regulate molecules associated with adaptive immunity 
such as MHCI.
mhcI
Because activation of adaptive immunity can be highly destructive, 
it is essential that it is activated only in response to foreign pro-
teins and not to self proteins (Janeway et al., 2005). The adaptive 
immune response is triggered by recognition of non-self antigens, 
which are displayed on antigen presenting cells (APCs) through 
MHC. MHCI proteins are cell-surface ligands that bind to T cell 
receptors (TCR) and other immunoreceptors and act to regulate 
the activation state of immune cells. One of the defining features 
of MHC molecules and their receptors is their complexity. They 
are both polygenic-containing multiple genes and polymorphic-
containing multiple variants of each gene. The MHC genes are 
the most polymorphic genes known (Janeway et al., 2005). The 
specific genes and variants that an individual expresses comprise 
its MHCI haplotype. The human MHC is encoded on chromo-
some 6 and contains 140 genes. In humans, there are three classical 
MHCI genes, the HLA class I antigens A, B, and C; the other MHCI 
genes are classified as non-classical. The rat MHC is encoded on 
chromosome 20 and contains a classical class I MHC-encoding 
region, RT1A, and other adjacent encoding regions including a 
non-classical class I MHC-encoding region, RT1-C/E/M. The 
RT1A region of the RT1 complex encodes between 1 and 3 clas-
sical class I molecules, depending on the rat strain. The mouse 
MHCI region is located on chromosome 17 and encodes the three 
H-2 genes – H2-K, H2-D, and H2-L. Each inbred mouse strain 
expresses a unique combination of MHCI molecules. Each of the 
classical MHCI molecules includes a β2-microglobulin (β2m) light 
chain, encoded by a single gene. Finally, the non- classical MHCI 
region in both rats and mice encodes numerous molecules, many 
of which have not yet been characterized even in the immune 
system (Abbas et al., 2000).
Classical MHCI molecules are trimeric proteins comprised of 
a transmembrane heavy chain, the β2m light chain, and a pep-
tide bound in the groove of the heavy chain. Complete trimers 
are transported to the cell surface of almost all cells in the body 
(Machold and Ploegh, 1996). Peptides presented by MHCI heavy 
chain on the cell surface are derived from proteolysis of intracel-
lular proteins and are monitored by T-cells. The T-cell repertoire 
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have dramatic effects on increasing cytokine expression in both 
neurons and glia. In turn, at least some cytokines like IFNγ upregu-
late MHCI expression in central and peripheral neurons in vitro 
and in vivo (Fujimaki et al., 1996; Zhou, 2009). However, in the 
past 10 years, discoveries that immune molecules are expressed 
Immune molecules are present In healthy  
neurons and glIa
It has been appreciated for years that stress, trauma, infection, and 
seizures can increase neural–immune cross-talk. These insults all 
Figure 2 | immune and neuronal synapses. Highly simplified schematics of 
these synapses illustrate the common core components of these asymmetric 
junctions. (A) A cytotoxic T-cell immune synapse is formed between an 
antigen-specific T-cell and a cell infected with an intracellular pathogen. The close 
junction is formed from a ring of adhesion proteins (purple cylinders) surrounding 
an inner signaling molecular domain of antigen receptors (MHCI; gray y) bound to 
T-cell receptors (TCR; blue Y). Cytokine receptors also cluster in the synapse (not 
shown in the diagram) where they are exposed to cytokines secreted into the 
synapse. (B, left) Activation of TCR signaling by MHCI molecules presenting 
non-self antigens (orange ovals) causes a signaling cascade resulting in 
polarization of the actin and microtubule cytoskeleton (blue lines) in the T-cell, 
recruitment of lytic granules (circles) and cell-surface receptors and co-
stimulatory molecules (including trans-synaptic adhesion molecules [purple 
ovals]) to the synapse, secretion of lytic granules (red) and apoptosis of the 
infected cell. (B, right) Conversely, TCR interaction with an MHC1 molecule 
containing a non-TCR specific peptide (orange ovals) does not affect microtubule 
reorganization and does not recruit lytic granules, resulting in termination of the 
contact and survival the APC. (C) The lytic natural killer (NK) cell immune synapse 
is also specialized for mediating cytotoxicity. An encounter between an NK cell 
and a target cell results in adhesion (orange ovals). The balance between 
activating and inhibitory receptor (pink) signaling at the cell–cell contact 
determines the outcome of the interaction. (D, left) A lack of MHCI on the target 
cell, caused by viral infection or tumorigenesis, triggers a signaling cascade in the 
NK cell resulting in reorganization of the actin cytoskeleton, clustering of 
cell-surface receptors (pink) and signaling molecules (blue) in the NK cell, 
recruitment and secretion of lytic granules, ultimately resulting in lysis of the 
target cell. (D, right) Conversely, the presence of MHCI (gray y) on the target cell 
results in binding of MHCI to NK inhibitory receptors, including PirB and Ly49s 
and initiates dominant inhibitory signaling, preventing the formation of the NK cell 
activation synapse and resulting in survival of the target cell. (e) Glutamatergic 
synapses in the mammalian CNS are comprised of several major protein classes. 
In the presynaptic axon terminal (blue), synaptic vesicles (circles) containing the 
neurotransmitter glutamate (blue) cycle at the active zone, which is composed of 
many kinds of proteins including presynaptic scaffolding proteins (blue Xs and 
hooks). The presynaptic terminal is separated from the postsynaptic dendrite 
(pink) by the synaptic cleft (yellow). A number of families of trans-synaptic 
adhesion molecules (blue ovals) span this cleft, providing a molecular connection 
capable of rapid signaling between the pre- and postsynaptic membranes. 
Glutamate receptors (gray), including AMPA and NMDA receptors, are found in 
the postsynaptic membrane, where they are associated with a large number of 
scaffolding and signaling proteins (pink rectangles) that together comprise the 
postsynaptic density. (F) If the synapse is weakened by long-term depression 
(LTD) then it can be eliminated (left), but if it is strengthened by long-term 
potentiation (LTP) then it will be stabilized and grow (right).
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tors have been examined using in situ hybridization and RT-PCR 
in rodent brains (Rothwell and Hopkins, 1995; Rothwell et al., 
1996; Meng et al., 1999; Ishii and Mombaerts, 2008). Confirming 
cytokine expression at the protein level in the CNS has been chal-
lenging and remains mostly incomplete given the purported lack 
of specificity of many commercially available antibodies necessary 
for western blot and immunocytochemistry experiments. Despite 
this caveat, it is clear that cytokines are produced by, and can act 
on, almost all CNS cells including neurons, astrocytes, and resi-
dent microglia (Hopkins and Rothwell, 1995; Mehler and Kessler, 
1995; Kaufmann et al., 2001; Kielian et al., 2002; Geppert, 2003; 
Harkness et al., 2003; Koyama et al., 2007). Interestingly, IFN-γ 
and is found at neuronal synapses (Vikman et al., 1998) suggest-
ing that it may act at the level of the synapse to influence brain 
function. In order to generate well-informed hypotheses for the 
function of cytokines in the healthy CNS, the field of neuroim-
munology must generate specific antibodies to cytokines and their 
receptors and use them to determine their distribution during 
development and plasticity. In addition, an understanding of the 
signaling mechanisms underlying cytokine function in neurons 
is needed to provide essential insights into the roles of cytokines 
that regulate normal and abnormal brain functions.
mhcI In the cns
Perhaps the biggest surprise in this field has been the discovery that 
many of the proteins central to the innate and adaptive immune 
responses are found on neurons and glia in the healthy brain 
(Ishii and Mombaerts, 2008). One of the first and most influen-
tial papers to demonstrate this constitutive expression was pub-
lished 12 years ago from the Shatz laboratory (Corriveau et al., 
1998). Using an unbiased PCR-based differential display screen 
for activity- regulated genes in the developing feline visual system, 
the Shatz lab discovered a substantial decrease in neuronal MHCI 
mRNA following activity blockade. Examination of the expression 
of several MHCI forms using in situ hybridization showed that 
MHCI molecules are expressed in unique, spatially and temporally 
restricted patterns in healthy, unmanipulated brains (Corriveau 
et al., 1998). Subsequently, MHCI mRNA and/or protein has been 
detected in several neuronal populations, including dorsal root 
ganglia neurons and brainstem motoneurons (Lidman et al., 1999; 
Loconto et al., 2003; Edstrom et al., 2004; Harnesk et al., 2009) as 
well as developing and adult hippocampal pyramidal (Neumann 
et al., 1997; Corriveau et al., 1998; Goddard et al., 2007; Ribic et al., 
2010) and cerebellar (Corriveau et al., 1998; McConnell et al., 2009) 
neurons. MHCI protein is also enriched in neuronal synaptic mem-
branes (Huh et al., 2000).
The search for the receptor through which MHCI functions in 
neurons has been much more challenging than initially expected. 
In the immune system, peptide-presenting MHCI molecules are 
usually thought to bind to T-cell receptors (TCRs) to mediate 
the adaptive immune response. However, there is no evidence 
for TCRα or TCR protein in neurons (Syken and Shatz, 2003; 
Boulanger and Shatz, 2004). Yet, many other immunoreceptors 
and associated effector molecules for MHCI such as PIRB (Syken 
et al., 2006; Atwal et al., 2008), Ly49 receptors (Zohar et al., 2008), 
KIR (Bryceson et al., 2005), and CD3ζ (Corriveau et al., 1998; Xu 
et al., 2010) are all found in the CNS where they display distinct 
in the healthy CNS and are essential for brain development have 
disproven the once-dominant paradigm of CNS immune privilege 
(Boulanger, 2009; Carpentier and Palmer, 2009; Deverman and 
Patterson, 2009). The presence of immune molecules in the CNS 
was overlooked until recently in large part because the expres-
sion patterns of many immune proteins in the CNS change over 
development and the levels of expression under normal healthy 
conditions tend to be quite low. This makes detecting mRNA and 
protein challenging and may have added to the misconception that 
immune molecules are only expressed in the CNS during periods 
of infection or trauma.
The nervous and immune systems share many proteins (Tian 
et al., 1999; Khan et al., 2001; Pacheco et al., 2004; Suzuki et al., 
2008), including cytokines, MHCI, and proteins of the complement 
system to name a few. Both systems also employ tightly control-
led communication through specialized, sophisticated cell–cell 
junctions called synapses (Figure 2; Yamada and Nelson, 2007). 
Confining the molecules released – neurotransmitters in the CNS 
and lytic enzymes and cytokines in the immune system – to syn-
apses ensures that they will act specifically and locally on target cells, 
with minimal effects on neighboring cells. Immunological synapses 
can form between a T-cell and an APC (Figure 2A) and between 
an NK cell and a target cell (Figure 2B; Yamada and Nelson, 2007). 
Just as the immune synapse transfers information and is neces-
sary for immune activation, the CNS synapse (Figure 2C) transfers 
information and is necessary for cognition. Although the synap-
tic localization of most immune molecules in neurons remains 
understudied, especially in vivo, several immune molecules and/or 
receptors, including some cytokines and their receptors (Vikman 
et al., 1998; Kubota et al., 2009), MHCI molecules (Huh et al., 2000) 
and components of the complement system (Stevens et al., 2007) 
have functions associated with synaptic changes in the healthy CNS 
(see Roles of immune molecules in the healthy CNS). It is tempting 
to speculate that immune molecules will play a similar role at the 
CNS synapse as at the immune synapse, but much more needs to 
be known about location and function of immune molecules in 
the CNS to draw direct parallels.
cytokInes In the cns
For years it has been well-established that many cytokines, 
chemokines, and their receptors are constitutively expressed in 
the brain throughout development and in the adult. Although 
many cytokines and their receptors remain unstudied, the major 
cytokines IL1-α, IL1-β, IL-4, IL-6, IL-10, IL-11, IL-13, IL-18, 
TNF-α, IL1-ra, TGF-β, and CCL2 are all expressed in the healthy 
CNS (Bauer et al., 2007). Many of these cytokines and their recep-
tors have differential expression patterns across the CNS that vary 
over development (Takao et al., 1992; Gadient and Otten, 1994; 
Pousset, 1994). For example, mRNAs for IL-6 and its receptor 
(IL-6R) are developmentally regulated in a tissue-specific manner 
in the rat brain (Gadient and Otten, 1994). The adult hippocampus 
has the highest detectable levels of both transcripts, while IL-6 
mRNA levels are highest during early brain development in most 
other brain regions. Levels of IL-6 mRNA can be dramatically 
upregulated with age; they increase up to 8-fold in the striatum 
during development (Gadient and Otten, 1994). In the majority 
of studies, the expression profiles of cytokines and their recep-
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play integral roles in the CNS throughout neural development, 
including affecting neurogenesis, neuronal migration, axon guid-
ance, synapse formation, activity-dependent refinement of circuits, 
and synaptic plasticity (Zhao and Schwartz, 1998; Deverman and 
Patterson, 2009). Complicating this already complex field is the 
observation that the functions of individual immune molecules in 
the nervous system may change over development. For example, 
during sequential stages of development, TGFβ regulates neural 
induction, cell lineage commitment, neuronal differentiation, axon 
growth and guidance (Pousset, 1994; Charron and Tessier-Lavigne, 
2007), and neuromuscular synapse formation and function (Sanyal 
et al., 2004; Feng and Ko, 2008; Heupel et al., 2008). Because we 
cannot adequately cover all of the roles for immune molecules in 
CNS development in a single review, we focus here on the effects 
of immune molecules on neuronal connections – specifically on 
the function, refinement, and plasticity of primarily geniculate, 
cortical and hippocampal synapses, and their relationship to neu-
rodevelopmental disorders.
refInement of connectIvIty
In order to create cohesive synaptic networks, appropriate connections 
must be formed and superfluous ones selectively eliminated. Most 
studies of the effects of immune molecules on refinement of con-
nections in the CNS during development have used one of the most 
classical models for activity-dependent refinement of  connections 
– visual system plasticity (Shatz, 2009). Visual information is carried 
from the retina through RGC axons into the lateral geniculate nucleus 
(LGN) of the thalamus and from there up to primary visual cortex. 
In binocular adult animals, axons carrying information from each 
eye are segregated into eye-specific layers in the LGN and into eye-
specific regions, called ocular dominance (OD) columns, in layer 4 
of visual cortex. Initially, inputs from each eye are thought to overlap 
in both the LGN and cortex and then become segregated later only 
after a period of activity-dependent synaptic refinement (Katz and 
Shatz, 1996). Studies from many laboratories have demonstrated that 
segregation of both retinogeniculate and geniculocortical axons is 
activity-dependent and involves competition between axons from 
each eye (Katz and Shatz, 1996; Hua and Smith, 2004). During criti-
cal periods, neural activity sculpts connections by strengthening and 
stabilizing subsets of synapses and weakening and eliminating others. 
If vision is restricted to only one eye during this critical period, the 
areas innervated by the deprived eye shrink while those innervated 
by the non-deprived eye expand (Katz and Shatz, 1996).
How neural activity ultimately leads to refinement is not well 
understood, but immune molecules appear to play an important 
role in this process. MHCI genes were first identified in the LGN 
in a screen for genes involved in the activity-dependent refinement 
of retinogeniculate axons (Corriveau et al., 1998). More recently, 
components of both the innate and adaptive immune systems – 
MHCI, its receptors, and complement – have been implicated in this 
process (Boulanger et al., 2001; Oliveira et al., 2004). The prevailing 
hypothesis in this field is that immune molecules in neurons engage 
MHCI receptors, generating common intracellular signals in both 
neurons and immune cells that ultimately alter synaptic strength, 
neuronal morphology, and circuit properties downstream of syn-
aptic activity (Boulanger et al., 2001; Syken et al., 2006; Fourgeaud 
and Boulanger, 2007).
gene expression and/or protein patterns and most are expressed 
in highly plastic regions. PirB is found throughout the CNS, and 
is present in the visual system during the period of activity-de-
pendent plasticity (Syken et al., 2006). PirB protein is localized to 
axonal growth cones and dendrites, where it is often very close to, 
but rarely overlaps with, the presynaptic proteins synaptophysin 
or synapsin, suggesting that PirB is localized near synapses (Syken 
et al., 2006). Ly49 mRNA is also amply expressed in the cerebral 
cortex, hippocampus, hypothalamus, and cerebellum in adult 
mouse brain (Zohar et al., 2008). Ly49 protein in neurites colo-
calizes with synapsin and alternates with the postsynaptic marker 
Shank (Zohar et al., 2008). KIR genes are selectively expressed 
in olfactory bulbs, rostral migratory stream, and dentate gyrus 
of hippocampus, subregions of the mouse brain where synaptic 
plasticity and neurogenesis occur (Bryceson et al., 2005). Finally, 
CD3ζ is also found throughout the developing and adult CNS and 
in the retina, where it is preferentially expressed by retinal ganglion 
cells (RGC) and colocalizes with PSD95 and CtBP2, a presynaptic 
ribbon protein in the IPL during the period of synaptic formation 
(Xu et al., 2010).
Mechanistically, MHCI may act through one or all of these 
receptors in an analogous fashion to its signaling in the immune 
system. However, the documented expression patterns of MHCI 
immunoreceptors do not adequately account for the documented 
functions (see below) and diversity of localization of specific MHCI 
forms. Thus, MHCI may bind multiple receptors or as yet uniden-
tified neuronal receptors. In the future, the subcellular distribu-
tion of MHCI in neurons, at synapses, and in all glial cell types 
must be determined in order to propose testable models for MHCI 
function. Proteomic and biochemical identification of all possible 
MHCI receptors and downstream signaling molecules, as well as 
the development of more specific antibodies to localize all of the 
MHCI and MHCI receptor subtypes, are essential to clarify these 
fundamental issues.
complement
In addition to cytokines and MHCI, essential components of the 
complement cascade, including C1q and C3, are also expressed in 
the CNS. They are expressed in a punctate pattern in the developing 
but not the adult brain, peaking during periods of synapse for-
mation and activity-dependent refinement (Perry and O’Connor, 
2008). In the retina, C1q protein is detected in immunostained 
cryosections in the synaptic inner plexiform layer (IPL) of postnatal 
mouse retinas and in developing RGCs. It colocalizes with synap-
tic proteins, postsynaptic density-95 (PSD-95) and synaptophysin 
puncta – mostly with one or the other of these proteins, but not 
often with both, at non-synaptic sites in the early postnatal retina. 
RGCs upregulate complement proteins in response to secreted mol-
ecules from astrocytes (Stevens et al., 2007). Moreover, C1q is often 
colocalized with MHCI at synapses between hippocampal neurons 
(Datwani et al., 2009), suggesting that these immune molecules 
may interact to alter synaptic function.
roles of Immune molecules In the healthy cns
Immune molecules are present at the right place and time to modu-
late the development and function of the healthy and diseased 
CNS. Indeed, recent research suggests that immune molecules 
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approach on RGCs, immature astrocytes were found to induce the 
expression of the C1qA, C1qB, C1q – components of the comple-
ment system – on neurons (Stevens et al., 2007). C1q localizes to 
synapses both in culture and in the postnatal CNS and this expres-
sion significantly declines by P30 (Stevens et al., 2007). Although 
the mechanism by which complement-tagged synapses might be 
eliminated has not been discovered, it is possible that microglia 
expressing the C3 receptor may be involved (Gasque et al., 1998). In 
motor neurons, microglia have been proposed to eliminate synapses 
via phagocytosis-synaptic stripping (Schiefer et al., 1999) and a 
similar process may occur in the CNS. Whether complement and 
MHCI molecules interact to regulate activity-dependent refine-
ment of connections has not yet been addressed. A major challenge 
for this field in the future will be to determine whether and how 
immune molecules interact mechanistically to alter connectivity 
in the developing CNS.
The role of cytokines and their receptors in refinement of con-
nections in the developing CNS is much less clear. However, two 
recent studies suggest that these diffusible factors are key players in 
this process. First, following monocular lid suture, mice deficient 
in TNFα show the normal initial decrease in cortical responses 
from the deprived eye, but do not show the subsequent increase 
in response to the open eye (Kaneko et al., 2008). Second, chronic 
exposure of Xenopus to TNFα decreases the number of immature 
synapses containing only NMDARs and no AMPARs on tectal neu-
rons. Thus, chronic exposure to this pro-inflammatory cytokine 
may cause premature maturation and stabilization of these syn-
apses (Lee et al., 2010). Interestingly, TNFα increases the growth 
of dendrites of tectal neurons and enhances connectivity, similar to 
what is seen in immature, less well-refined tectal circuits (Lee et al., 
2010). Given the widespread effects of many cytokines on synaptic 
plasticity (see below), especially long-term potentiation and depres-
sion which are believed to underlie activity-dependent refinement 
of connections (Hensch et al., 1998), it is likely that many members 
of the large family of cytokines will also play important roles in 
refinement of connections in the developing brain.
Although exuberant connectivity in the visual system in β2m/
TAP1 DKO, PirB KO, H2-Kb/H2-Db DKO, C1q KO, and C3 KO 
mice has been interpreted to indicate a lack of synapse elimination, 
it is equally possible that this phenotype is the result of increased 
axonal growth, synapse formation, and/or synapse stabilization. 
Clarifying this issue is absolutely critical to understand how these 
molecules alter activity-dependent refinement of connections. Yet, 
there is currently no assay available that can distinguish whether a 
molecule changes synapse density through altering the formation 
or elimination of synapses. Development of new assays allowing 
long-term imaging of synaptic connections is critical to address 
this fundamental issue in the future.
synaptIc transmIssIon
In addition to mediating activity-dependent refinement of con-
nections during CNS development, many immune molecules also 
regulate synaptic transmission between hippocampal and cortical 
neurons. For example, MHCI molecules affect basal transmission 
at glutamatergic synapses in cultured hippocampal neurons and 
cortical slices. β2m/TAP1 DKO mice exhibit slightly larger presy-
naptic terminals in cultured hippocampal neurons and a small 
Consistent with this idea, transgenic mice have been used to 
discover dramatic effects of immune molecules on refinement of 
connectivity during brain development. In order to determine the 
role for MHCI during activity-dependent plasticity, retinogenicu-
late projections were examined in β2m/TAP1 double-knockout 
(DKO) mice, in which MHCI on the surface of their cells is dra-
matically decreased due to the lack of β2m, the MHCI light chain 
required for transport of MHCI to the membrane, and the trans-
porter associated with antigen processing 1 (TAP1), which packages 
proteasomal peptides required for most MHCI receptor-mediated 
signaling (Abbas et al., 2000). These β2m/TAP1 DKO mice have a 
significantly larger projection from the ipsilateral eye in the LGN 
(Corriveau et al., 1998; Huh et al., 2000), interpreted as indicating 
a lack of pruning of the inappropriate retinogeniculate axons. A 
similar impairment of refinement of retinogeniculate layers was 
found in an MHCI KO mouse lacking both H2-Kb and H2-Db 
genes (Datwani et al., 2009) and in mice lacking CD3ς (Huh et al., 
2000). Interestingly, OD plasticity was enhanced in the KbDb KO 
mouse (Datwani et al., 2009), further supporting the conclusion 
that MHCI might be critical for mediating the effects of activity in 
modifying neural connections (Huh et al., 2000). Because the PirB 
KO mouse phenocopies the enhanced OD plasticity in the KbDb 
KO, PirB is likely the MHCI receptor in cortex (Syken et al., 2006; 
Datwani et al., 2009). However, retinogeniculate remodeling was 
unaltered in the PirB KO (Syken et al., 2006), implying that there 
are likely additional means by which MHCI molecules exert their 
effects in the developing LGN.
Although the hypothesis that MHCI acts at CNS synapses to 
mediate activity-dependent synaptic weakening and elimination of 
inappropriate connections (Shatz, 2009) is consistent with effects 
of MHCI on synaptic plasticity (see below), a recent report has 
suggested an alternate hypothesis – that MHCI contributes to reti-
nogeniculate refinement indirectly by altering the structure and 
function of RGCs (Xu et al., 2010). CD3ς is expressed in RGCs 
and CD3ς-deficient mice exhibit reduced RGC dendritic motil-
ity, an increase in RGC dendritic density, and a selective defect of 
glutamate-receptor-mediated synaptic activity in the retina (Xu 
et al., 2010). In contrast with previously reported hypotheses that 
MHCI directly regulates refinement, this change in glutamate-
receptor-mediated synaptic activity suggests that MHCI may 
instead be altering activity patterns and thus indirectly affecting 
refinement. Furthermore, it is clear that MHCI is not required for 
all forms of activity-dependent refinement since loss of MHCI 
molecules does not alter refinement of climbing fiber-Purkinje 
cell projections (Letellier et al., 2008; McConnell et al., 2009). 
Thus, the roles for MHCI in refinement of connections during 
CNS development may be complex and system-specific. There is 
much to be done to fully understand the effects of these immune 
molecules in brain development. Elucidating the precise role for 
MHCI molecules and its receptors in synaptic refinement is a criti-
cal issue for this field.
Classical complement proteins also play a role in retinogenicu-
late refinement. Like those seen in the β2m/TAP DKO mice, defects 
in eye-specific segregation occur in mice in which components 
of the complement cascade are knocked out (C1q and C3 KOs), 
thus complement may mediate activity-dependent elimination of 
exuberant connections (Stevens et al., 2007). Using a gene profiling 
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the effects of immune molecules on inhibition, future studies are 
necessary to better understand the potential effects of immune 
molecules on the ratio of excitatory-to-inhibitory synapses.
synaptIc plastIcIty
The cellular mechanisms underlying activity-dependent refinement 
of connections during CNS development are thought to involve a 
regulated combination of Hebbian synaptic plasticity –long-term 
plasticity (LTP) and long-term depression (LTD) – and homeostatic 
plasticity. Many immune molecules studied to date modulate one 
or both of these forms of long-term plasticity (Bauer et al., 2007; 
Boulanger, 2009).
LTP/LTD
Although the mechanisms through which MHCI molecules regu-
late activity-dependent refinement of circuits are yet unclear, many 
manipulations of MHCI result in changes to long-term plastic-
ity. Hippocampal LTP is enhanced (Huh et al., 2000; Barco et al., 
2005) and LTD is abolished at standard stimulation frequencies in 
β2m/TAP1 DKO mice (Huh et al., 2000). Like MHCI, CD3ζ is also 
required for hippocampal LTD and limits LTP (Huh et al., 2000). 
Finally, another signaling component of MHCI receptors in immune 
cells – DAP12 – also limits LTP (Roumier et al., 2004, 2008). Together 
these results support the interpretation that MHCI molecules play 
an integral role in activity-dependent plasticity specifically by 
enhancing synapse weakening and possibly elimination.
The role for MHCI in long-term plasticity is dependent upon 
the circuit analyzed. Two specific MHCI molecules, H2-Kb and 
H2-Db increase the threshold for LTD at parallel fiber (PF)-PC 
synapses in the adult cerebellum. Mice deficient in both these forms 
of MHCI show improved performance on the rotarod behavioral 
test, indicative of enhanced cerebellar plasticity (McConnell et al., 
2009). Interestingly, rotarod performance at high speed is reduced 
in CD3ε KO mice (Nakamura et al., 2007) while similar tests on 
CD3ζ KO mice and PirB deficient mice show no impairments 
(McConnell et al., 2009). Future studies are needed to determine 
if and how MHCI alters long-term plasticity in different areas of 
the CNS using similar or distinct mechanisms.
Similar to MHCI molecules and its co-receptors, a grow-
ing number of cytokines, including TNF-α, IL-1β (Katsuki 
et al., 1990; Cunningham et al., 1996; Spulber et al., 2009), IL-2 
(Tancredi et al., 1990), IL-6 (Bellinger et al., 1995; Li et al., 1997; 
Tancredi et al., 2000), IL-8 (Xiong et al., 2003), IL-18 (Curran and 
O’Connor, 2001; Alboni et al., 2010), TGFβ, and interferon-α 
and -β (D’Arcangelo et al., 1991; Mendoza-Fernandez et al., 2000) all 
inhibit hippocampal LTP. These cytokine-induced effects are dose-
dependent and mediated by distinct receptors (D’Arcangelo et al., 
1991). Exogenous TNFα may inhibit LTP (Tancredi et al., 1992) 
and LTD is abolished in mice lacking the TNF receptor (Albensi 
and Mattson, 2000). The role of TNFα in LTP and LTD has been 
questioned, however, by recent results published by two groups 
showing no impairment in hippocampal and cortical LTP and LTD 
in TNFα- and TNFR-deficient mice (Stellwagen and Malenka, 2006; 
Kaneko et al., 2008). IL-6 and IL-2 inhibit LTP and short-term 
potentiation (STP) in a dose-dependent manner (Li et al., 1997). 
In addition, IL-1β, IL-6, and TNF-α regulate synaptic plasticity in 
models of learning and memory and have been  associated with 
(10%) but significant increase in the number of synaptic vesicles 
at synapses in adult hippocampal slices as determined by elec-
tron microscopy (Goddard et al., 2007). Consistent with these 
changes in synaptic composition, mEPSCs are altered in cultured 
hippocampal neurons from β2m/TAP1 DKO mice compared to 
controls. mEPSC frequency increases by 40% in hippocampal DKO 
cultures and by over 100% in acute cortical slices from DKO mice, 
while mEPSC amplitude is unchanged. Because the authors did 
not detect a change in synapse density in their DKO hippocam-
pal cultures, they interpreted the increase in mEPSC frequency as 
due to a change in synaptic vesicle release probability (Goddard 
et al., 2007). The cause of the 100% increase in mEPSC frequency 
in cortical slices was not assessed. Finally, H2-KbDb DKO mice 
show enhanced presynaptic glutamate release at climbing fiber 
(CF)-Purkinje cell (PC) synapses in the cerebellum (McConnell 
et al., 2009). Measures of postsynaptic function, including mEPSC 
amplitude, were not altered by manipulation of MHCI levels in 
either system, suggesting that MHCI molecules selectively regulate 
synaptic vesicle release.
Several cytokines also alter synaptic transmission, but the 
nature of their effects is highly dependent on the specific cytokine 
studied and its dose. For example, recombinant IL-1β decreases 
the frequencies but not the amplitudes of spontaneous excitatory 
postsynaptic currents (sEPSC) and mEPSCs in cultured hippoc-
ampal neurons. IL-1β also increases the NMDA receptor-mediated 
current and the amplitude of the voltage-dependent Ca2+current 
(I
Ca
), in a dose-dependent manner (Yang et al., 2005). Conversely, 
recombinant TGFβ2 increases both the frequency and amplitude 
of mEPSCs in hippocampal neurons (Fukushima et al., 2007). 
Similarly, recombinant TNF-α increases mEPSC frequency and 
amplitude and enhances EPSPs (Beattie et al., 2002; Stellwagen 
et al., 2005; Stellwagen and Malenka, 2006). TNFα works in large 
part by promoting the surface accumulation of AMPA-type gluta-
mate receptors (AMPARs) in hippocampal neurons in vitro (Beattie 
et al., 2002). TNFα appears to work primarily postsynaptically since 
there is no effect on paired-pulse facilitation, a measure of presyn-
aptic function (Beattie et al., 2002). Similarly, blocking endogenous 
TNFα using a soluble TNF receptor, sTNFR1, decreases mEPSC 
frequency and amplitude, surface AMPAR levels, and the AMPA/
NMDA ratio in hippocampal slices (Beattie et al., 2002; Stellwagen 
et al., 2005). While it is unclear if all cytokines are released from 
glia, the endogenous TNFα that alters synaptic transmission does 
come primarily from glial sources (Beattie et al., 2002; Stellwagen 
et al., 2005).
In contrast to their effects on the function of excitatory synapses, 
the effects of immune molecules on inhibitory synapses remain 
mostly unknown. MHCI may control GABAergic inputs since it is a 
target of the transcription factor Npas4, which enhances GABAergic 
synapse density (Lin et al., 2008). Likewise, several cytokines, 
including IL-1β (Zeise et al., 1992) and TNF-α (Stellwagen et al., 
2005) regulate inhibitory synaptic transmission. Recombinant 
IL-1β inhibits GABAergic currents and GABAergic synaptic 
transmission in hippocampal neurons (Zeise et al., 1992; Wang 
et al., 2000). Similarly, recombinant TNFα decreases the strength 
of GABAergic synapses (Stellwagen et al., 2005), suggesting that 
TNFα could mediate the balance between excitation and inhibi-
tion on hippocampal neurons. Because so little is known about 
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in synaptic strength in response to activity blockade with TTX 
(Stellwagen and Malenka, 2006). However, TNFα does not medi-
ate the corresponding decrease in synaptic strength produced by 
increased neuronal activity (Stellwagen and Malenka, 2006). The 
ability of TNFα to alter AMPAR trafficking in response to activity-
blockade is mediated through upregulation of β3 integrin expres-
sion (Cingolani and Goda, 2008). Loss of TNFα through genetic 
knockout or pharmacological inhibition also blocks homeostatic 
synaptic scaling of mEPSCs in visual cortex in acute slices and 
in vivo (Kaneko et al., 2008). Similarly, pharmacological block-
ade of TNF activity prevents the TTX-induced decrease in mIPSC 
amplitude, indicating that TNFα mediates homeostatic scaling of 
both excitatory and inhibitory synapses (Stellwagen et al., 2005; 
Stellwagen and Malenka, 2006). Finally, the TNFα KO mouse shows 
normal loss of responses to the deprived eye following monocu-
lar deprivation but no subsequent compensation by the open eye 
(Kaneko et al., 2008), supporting the conclusion that TNFα medi-
ates homeostatic plasticity both in vitro and in vivo. Although there 
are differences in the phenotypes observed between the TNF KO 
and the MHCI-deficient mice, MHCI in neurons and astrocytes 
can be regulated by TNFα (Lavi et al., 1988; Neumann et al., 1997; 
Sourial-Bassillious et al., 2006), and thus some of the effects of 
TNF-α could be mediated by changing MHCI levels in neurons. 
This possible interaction underscores the importance of future 
work in defining the mechanisms used by these immune molecules 
to alter plasticity, and their potential overlapping pathways.
ImplIcatIons for neurodevelopmental dIsorders
The formation of functional neuronal circuits in the CNS during 
development provides the substrate for human learning, memory, 
perception, and cognition. Improper formation or function of these 
synapses may lead to a number of neurodevelopmental disorders 
including ASD and schizophrenia. ASD and schizophrenia are com-
plex diseases that appear to be caused by combinations of genetic 
changes and environmental insults during early development 
(Boulanger, 2004; Arion et al., 2007; Patterson, 2009). Although a 
wide range of environmental stimuli have been proposed to play 
a role in the pathogenesis of these disorders, many of these stimuli 
have in common the ability to alter immune function.
The link between environmental factors, the immune response, 
and neurological dysfunction is not completely clear at present, 
but it is receiving increasing attention and support. Multiple stud-
ies have associated schizophrenia and ASD with autoimmunity 
and allergies (Sperner-Unterweger, 2005; Arion et al., 2007). In 
both schizophrenia and ASD, evidence is growing that there are 
abnormalities in peripheral immune cells, as well as associations 
with specific genetic variants in cytokines, cytokine receptors, and 
MHCI genes (Daniels et al., 1995; Warren et al., 1996; Shi et al., 
2009a; Stefansson et al., 2009). In addition, a polymorphism of the 
cytokine interleukin-1 (IL-1) gene complex appears to be linked 
to schizophrenia (Hanninen et al., 2008). Finally, interleukin-1 
receptor accessory protein-like 1(IL1RAPL1) gene mutations are 
associated with cognitive impairment ranging from non-syndromic 
X-linked mental retardation to autism (Pavlowsky et al., 2010).
It is not necessary, however, that immune genes themselves be 
mutated to yield the alterations observed in a diseased brain, as 
expression and signaling of these factors can be dynamically altered 
cognitive decline and dementia (Schmidt et al., 2002; Holmes 
et al., 2003; Dik et al., 2005). Moreover, IL-1β blocks induction 
of LTP in the mossy fiber CA3 pathway of mouse hippocampal 
slices (Katsuki et al., 1990) and this effect can be mimicked with 
TNF-α and LPS in slices (Katsuki et al., 1990; Cunningham et al., 
1996). IL-18 depresses the amplitude of pharmacologically isolated 
NMDA receptor-mediated fEPSPs and impairs LTP in hippocampal 
slices (Curran and O’Connor, 2001). Finally, LTP induction in turn 
upregulates levels of IL-1β, TGFβ, and IL-6 (Jankowsky et al., 2000; 
Balschun et al., 2004). Thus, alterations in the levels of cytokines 
can profoundly change synaptic efficacy, and changes in synaptic 
function can alter cytokine levels. Because all of the cytokines tested 
so far limit LTP, it is important in the near future to determine if 
they act through common or distinct pathways to alter mechanisms 
of LTP expression.
Synaptic scaling (homeostasis)
In addition to their effects on Hebbian plasticity, immune mol-
ecules have also been implicated in the regulation of homeostatic 
plasticity. The concept of homeostasis is ubiquitous in biology. In 
order to maintain balance in any system, a method to insure that 
it can function independently of fluctuating environments must 
be in place. In neural networks, this homeostatic mechanism is 
known as synaptic scaling or homeostatic plasticity (Turrigiano, 
2008). Synaptic scaling occurs in both cultured neurons and in hip-
pocampal slices, although in slice it appears to be heterogeneous, 
varying in both a target- and afferent-specific manner (Kim and 
Tsien, 2008). Dynamic, activity-dependent AMPAR trafficking may 
underlie synaptic scaling and is seen in several experience-driven 
phenomena – from neuronal circuit formation to alterations of 
behavior (Kessels and Malinow, 2009). Synaptic homeostasis is 
thought to prevent positive feedback mechanisms in neural circuits 
from destabilizing over time and becoming hyper- or hypo-active 
(Desai et al., 2002; Ibata et al., 2008; Turrigiano, 2008; Gainey et al., 
2009; Savin et al., 2009).
MHCI molecules have been implicated in mediating homeo-
static plasticity. Blocking action potentials with tetrodotoxin (TTX) 
in the LGN in vivo decreases levels of MHCI mRNA (Corriveau 
et al., 1998) and in cultured hippocampal neurons decreases levels of 
MHCI protein (Goddard et al., 2007). Because neither synapsin nor 
PSD-95 increase in size in response to TTX in β2m/TAP1 DKO mice 
as they do in WT mice (Goddard et al., 2007), it has been suggested 
that changing MHCI levels might mediate the increase in synaptic 
strength caused by chronic activity blockade. Presynaptic proteins 
were already increased in size in these DKO mice and thus, might 
have occluded presynaptic-mediated synaptic scaling (Goddard et al., 
2007). However, MHCI molecules are clearly important for increas-
ing the size of postsynaptic scaffolding proteins in response to activity 
blockade. How these immune molecules might read out the effects 
of neural activity is not yet known and is one of the most exciting 
open questions in this field.
Although most cytokines have not yet been studied in synaptic 
scaling, TNFα clearly plays an important role in mediating homeo-
static plasticity. Exogenous TNFα modulates synaptic strength in 
hippocampal neurons by rapidly promoting surface expression of 
AMPA receptors (Beattie et al., 2002; Stellwagen et al., 2005). TNFα 
secretion from glia, but not neurons, mediates the robust increase 
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identified include reduced NMDA receptor expression in hippocam-
pus and enhanced tyrosine hydroxylase in striatal structures. In the 
prefrontal cortex, the numbers of reelin- and parvalbumin-positive 
cells as well as dopamine D1 and D2 receptors were also reduced 
(Meyer et al., 2008a,b). Adult offspring display increased levels of 
GABAA receptor α2 immunoreactivity and dopamine hyperfunc-
tion as seen in schizophrenia (Yee et al., 2005). Importantly, the tim-
ing of MIA determines the nature and extent of the neuropathology 
and behavioral outcome (Meyer et al., 2006; Fatemi et al., 2008), as 
well as the types of cytokines that are acutely activated within hours 
of MIA (Meyer et al., 2006).
Cytokines released by the mother’s immune response can cross 
the placenta and cause the pathological and behavioral changes 
exhibited by virally infected or PolyI:C-injected mice (Patterson, 
2002). LPS-induced MIA alters placental cytokines (IL-1β, IL-6, 
and TNF-α) and induces cytokines (IL-1β, IL-6, TNF-α, and IFN) 
in the fetus. Specifically, IL-6 is upregulated in the placenta and 
amniotic fluid after MIA and it can cross the BBB in early to mid-
gestation (Smith et al., 2007; Patterson, 2009). IL-6 injection of 
pregnant dams in mid-gestation mimics the effects of immune 
activation on neuropathology and behavior, and the effects of 
PolyI:C on fetal brain development and subsequent behavior are 
prevented by co-injection of an IL-6 antibody (Smith et al., 2007). 
Moreover, maternal injection of poly (I:C) in an IL-6 knockout 
mouse results in offspring with normal behavior. In addition 
to preventing the development of abnormal behaviors, the IL-6 
antibody also blocks the changes in brain transcription induced 
by maternal poly (I:C) (Smith et al., 2007). These elegant studies 
demonstrate that elevation of maternal cytokines during gestation 
can cause neuropathology and abnormal behaviors in offspring 
consistent with several neurodevelopmental disorders, including 
schizophrenia and ASD.
Despite recent progress in developing and characterizing mouse 
models of MIA, little is known about how maternal cytokines alter 
fetal brain development. One possibility is that maternal cytokines 
cross into the fetal brain, where they cause neuroinflammation 
(Patterson, 2009). Several reports have recently identified increases 
in cytokine levels in fetal brain following MIA, but these studies 
were performed only shortly after PolyI:C injection (2–4 h), pooled 
multiple brain areas, and focused on only a few cytokines (Gilmore 
et al., 2005; Meyer et al., 2006; Patterson, 2009). These reports found 
significant increases in IL-1β and IL-6 in fetal brains 6 h after mater-
nal PolyI:C injection (Meyer et al., 2006). Another recent report 
showed that IL-6 levels are increased in the fetal brain after mul-
tiple IL-6 injections of pregnant rats and remain elevated in these 
offspring at 4 and 24 weeks of age (Patterson, 2009). This chronic 
elevation of a cytokine in the fetal rat brain is similar to the chronic 
elevation of a panel of cytokines and chemokines found in the brains 
and CSF of autistic individuals. IL-6, IL-10, and TGFβ (out of 13 
cytokines tested) were significantly increased in cortical tissue of 
autistic individuals, while 10 out of 20 chemokines were elevated 
in autistic brain, including MCP-1 (also called CCL2; Vargas et al., 
2005). In another study, TNFα was elevated in CSF from 10 autistic 
children with a history of regression (Chez et al., 2007). Finally, 
many immune-related genes, including several cytokines, their 
receptors, and other elements of their signaling pathways, have been 
reported to be elevated in serum from autistic individuals compared 
by many environmental influences, including stress,  infection, 
 hormones, and brain activity. Accumulating evidence suggests that 
abnormalities in cytokine levels both systemically and in the CNS 
may be responsible for changes in brain connectivity associated 
with neurodevelopmental disorders. Elevated levels of the pro-
 inflammatory cytokines IL-6, TNF-α and IL-1β have been found in 
the cerebrospinal fluid (CSF), blood, and post-mortem brain tissue 
of people with autism (Vargas et al., 2005). These three cytokines 
have also been associated with schizophrenia (Monji et al., 2009) 
and epilepsy (Galic et al., 2008; Vezzani et al., 2008). Moreover, 
microglial and astrocyte activation is concurrent with cytokine 
up-regulation in the autistic brain and CSF (Vargas et al., 2005; 
Saetre et al., 2007).
Whether these increases in cytokines and/or mutations in 
immune molecules cause neurodevelopmental disorders is 
unknown. Because immune molecules directly alter development 
and cognition, any changes in the levels of these molecules could 
contribute to disease. It may be that connectivity in the CNS is 
altered by effects of immune molecules directly on synaptic trans-
mission, refinement of connectivity, plasticity, and/or synaptic 
scaling. But what is the origin of the initial imbalance? Although 
neurodevelopmental disorders could cause immune dysregulation, 
growing evidence suggests that maternal immune activation (MIA) 
may lead to developmental abnormalities in the CNS. MIA has 
recently received much attention in the ASD field because several 
known factors that alter the fetal environment can increase the 
risk for ASD. Maternal exposure to valproic acid or thalidomide 
greatly increases the risk for ASD in children (Patterson, 2009) and 
maternal viral infection has been called “the principle non-genetic 
cause of autism” (Ciaranello and Ciaranello, 1995). Large-scale epi-
demiological studies will soon illuminate the true contribution of 
maternal infection to ASD. Similar data support the hypothesis that 
MIA might contribute to schizophrenia, including the controversial 
observation that maternal influenza infection during gestation may 
be a risk factor for schizophrenia (Mednick et al., 1988; Mak et al., 
2008; Short et al., 2010).
Mouse models of MIA support the hypothesis that a periph-
eral immune response during development alters CNS structure 
and function. Adult offspring of pregnant mice given intra-nasal 
influenza virus on embryonic day 9.5 (E9.5) exhibit behavioral 
abnormalities including a deficit in social interaction, reluctance 
to interact with a novel object, deficient prepulse inhibition and 
increased anxiety under mildly stressful conditions (Shi et al., 2003), 
as well as changes in brain structure (Fatemi et al., 2002; Shi et al., 
2003; Fatemi et al., 2008; Shi et al., 2009b). Many of these abnor-
malities are similar to those associated with ASD and schizophrenia. 
Because the virus was not detected in the fetus in this mouse model, 
it is the maternal immune response to influenza infection that causes 
these behavioral abnormalities (Shi et al., 2005). Indeed, many of 
these abnormal behaviors can also be elicited in the absence of infec-
tion by activating the maternal immune response with synthetic 
dsRNA (polyI:C) injection, which acts to initiate an inflammatory 
response similar to that caused by viral infection (Shi et al., 2003). 
The hallmark structural abnormality in schizophrenia, ventricular 
enlargement, is also observed in the poly (I:C) MIA mouse model 
along with a delay in hippocampal myelination (Jaaro-Peled et al., 
2007; Piontkewitz et al., 2007). Other  neuropathological changes 
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neuroinflammation? It may be that the similarities between the 
nervous and immune systems provide insight into this question. 
The developing immune system may be as vulnerable during this 
developmental window as the nervous system. A fetus’ immunity 
in utero is poorly developed, what little defenses it does have are 
contiguous with its mother (Inman et al., 2010). Infants have the 
capability to develop some responses to antigens at birth, but a lot 
of their initial immunity is passively acquired from their mother 
during pregnancy and after, from breast milk (Goldman et al., 1996; 
Srivastava et al., 1996; Wallace et al., 1997; Garofalo and Goldman, 
1998; Hawkes et al., 1999; Garofalo, 2010). The immune system is 
composed of a detailed network of balanced cascades. If this delicate 
balance is disrupted during this critical time of life, in utero and 
during the postpartum period, it may cause permanent deficits 
resulting in an imbalance and hyper-responsiveness manifested 
as immune dysregulation accompanied by neuroinflammation 
throughout life.
fInal thoughts
The relationship between the immune and nervous systems is 
much more complicated than once thought (Figure 3). Immune 
molecules mediate essential nervous system functions during 
healthy development independent of immune and inflammatory 
processes (Bauer et al., 2007; Boulanger, 2009). The immune 
system appears to influence the nervous system during typical 
to  controls (Pardo et al., 2005; Ashwood et al., 2006; Garbett et al., 
2008; Meyer et al., 2008a; Enstrom et al., 2009). Together, these data 
support the hypothesis that MIA leads to chronic neuroinflamma-
tion that alters CNS development and behavior and may contribute 
to neurodevelopmental disorders (Patterson, 2002, 2009).
Although viruses and bacteria cannot cross the placenta, some 
cytokines can. In the poly (I:C) MIA model, IL-6 crosses the pla-
centa and induces an immunological response in the unborn fetus 
and developing brain. During development in utero, the brain is 
extremely vulnerable (Oliver et al., 1997). Not only is it not fully 
developed until well after birth, but the BBB is highly permeable 
during this critical time. Gene and protein expression in the brain 
suggest a precise temporal and spatial role for immune modulators 
during this period. A surge in immune activation early in develop-
ment may be extremely detrimental, if not fatal (Korteweg and Gu, 
2008; Basurko et al., 2009; Carcopino et al., 2009). If brain circuits 
are altered during a later developmental window, gross defects may 
be spared, but more subtle changes, perhaps affecting synaptic 
strength or plasticity may occur. Intriguingly, pro-inflammatory 
cytokines such as IL-1, IL-6, and TNF-α, elevated in neurodevelop-
mental disorders, are known to serve specific functions in synaptic 
plasticity and cognitive processes (see above).
Immune dysregulation in neurodevelopmental disorders is not 
only seen as a correlation to an initial insult, but may occur through-
out the lifespan of the individual. What is the impact of chronic 
Figure 3 | The relationship between the immune system and nervous 
system is highly complicated. However, it is now apparent that immune 
molecules not only cross the blood–brain barrier in times of injury, but are 
expressed during normal brain development. Recent evidence suggests roles 
for MHCI and its receptors, complement, and cytokines on the function, 
refinement, and plasticity of cortical and hippocampal synapses. These functions 
for immune molecules during neural development suggest that they could also 
mediate pathological responses to chronic elevations of cytokines in 
neurodevelopmental disorders, including autism spectrum disorders (ASD) and 
schizophrenia.
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molecules will change their functions over development and will 
affect one another, but how this will affect neural function and 
development is also completely unknown. Rapid progress in this 
newly energized and exciting field holds tremendous promise not 
only for enhancing our understanding of typical development, 
but also for elucidating and potentially even treating neuropsy-
chiatric disorders.
acknowledgments
We wish to thank Daniel Braunschweig, Samantha Spangler, 
Stephanie Barrow, Leigh Needleman, Brad Elmer, and Myka 
Estes for comments on the manuscript and Cure Autism Now, 
the Higgins Family Foundation, The Bernard Gassin Family 
Foundation, the John Merck Fund, Autism Speaks, and NARSAD 
for funding our research into the roles for immune molecules in 
synapse formation.
functioning and in disease. Chronic infection or severe illness 
may disrupt the balance of normal neural–immune cross-talk 
resulting in permanent structural changes in the brain during 
development, and/or contributing to pathology later in life. The 
diversity, promiscuity, and redundancy of “immune” signaling 
molecules allow for a complex coordination of activities and 
precise signaling pathways, fundamental to both the immune 
and nervous systems. However, the sheer number of immune 
molecules that could be important for nervous system develop-
ment and function is staggering. Although much progress has 
been made in the past 10 years in our appreciation that immune 
molecules play critical roles in the healthy brain, the large major-
ity of immune molecules have not yet been studied for their 
presence and function in the brain. For the immune molecules 
that we know are important, almost nothing is understood about 
their mechanisms of action. There is no doubt that many immune 
Frontiers in Synaptic Neuroscience www.frontiersin.org September 2010 | Volume 2 | Article 136 | 14
Garay and McAllister Immune molecules in neural development
responses to LTP induction in the 
rat hippocampus: a comparison of 
in vitro and in vivo techniques. Learn. 
Mem. 7, 400–412.
Kaneko, M., Stellwagen, D., Malenka, 
R. C., and Stryker, M. P. (2008). 
Tumor necrosis factor-alpha medi-
ates one component of competitive, 
experience-dependent plasticity in 
developing visual cortex. Neuron 58, 
673–680.
Katsuki, H., Nakai, S., Hirai, Y., Akaji, 
K., Kiso, Y., and Satoh, M. (1990). 
Interleukin-1 beta inhibits long-term 
potentiation in the CA3 region of 
mouse hippocampal slices. Eur. J. 
Pharmacol. 181, 323–326.
Katz, L.C., and, Shatz, C. J. (1996). Synaptic 
activity and the construction of corti-
cal circuits. Science 274, 1133–1138.
Kaufmann, A., Salentin, R., Gemsa, D., 
and Sprenger, H. (2001). Increase 
of CCR1 and CCR5 expression and 
enhanced functional response to 
MIP-1 alpha during differentiation of 
human monocytes to macrophages. J. 
Leukoc. Biol. 69, 248–252.
Kessels, H. W., and Malinow, R. (2009). 
Synaptic AMPA receptor plasticity and 
behavior. Neuron 61, 340–350.
Khan, A. A., Bose, C., Yam, L. S., Soloski, M. 
J., and Rupp, F. (2001). Physiological 
regulation of the immunologi-
cal synapse by agrin. Science 292, 
1681–1686.
Kielian, T., van Rooijen, N., and Hickey, W. 
F. (2002). MCP-1 expression in CNS-1 
astrocytoma cells: implications for 
macrophage infiltration into tumors 
in vivo. J. Neurooncol. 56, 1–12.
Kim, J., and Tsien, R. W. (2008). Synapse-
specific adaptations to inactivity in 
hippocampal circuits achieve homeo-
static gain control while dampening 
network reverberation. Neuron 58, 
925–937.
Korteweg, C., and Gu, J. (2008). Pathology, 
molecular biology, and pathogenesis 
of avian influenza A (H5N1) infec-
tion in humans. Am. J. Pathol. 172, 
1155–1170.
Koyama, Y., Baba, A., and Matsuda, T. 
(2007). Production of monocyte che-
moattractant protein-1 and cytokine-
induced neutrophil chemoattractant-1 
in rat brain is stimulated by intracer-
ebroventricular administration of 
an endothelin ETB receptor agonist. 
Neuroreport 18, 1275–1279.
Krzewski, K., and Strominger, J. L. (2008). 
The killer’s kiss: the many functions of 
NK cell immunological synapses. Curr. 
Opin. Cell Biol. 20, 597–605.
Kubota, K., Inoue, K., Hashimoto, R., 
Kumamoto, N., Kosuga, A., Tatsumi, 
M., Kamijima, K., Kunugi, H., Iwata, N., 
Ozaki, N., Takeda, M., and Tohyama, M. 
(2009). Tumor necrosis factor recep-
tor-associated protein 1 regulates cell 
adhesion and synaptic morphology via 
Hawkes, J. S., Bryan, D. L., James, M. J., 
and Gibson, R. A. (1999). Cytokines 
(IL-1beta, IL-6, TNF-alpha, TGF-
beta1, and TGF-beta2) and pros-
taglandin E2 in human milk during 
the first three months postpartum. 
Pediatr. Res. 46, 194–199.
Hensch, T. K., Gordon, J. A., Brandon, E. 
P., McKnight, G. S., Idzerda, R. L., and 
Stryker, M. P. (1998). Comparison of 
plasticity in vivo and in vitro in the 
developing visual cortex of normal 
and protein kinase A RIbeta-deficient 
mice. J. Neurosci. 18, 2108–2117.
Heupel, K., Sargsyan, V., Plomp, J. J., 
Rickmann, M., Varoqueaux, F., Zhang, 
W., and Krieglstein, K. (2008). Loss 
of transforming growth factor-beta 2 
leads to impairment of central synapse 
function. Neural Dev. 3, 25.
Holmes, C., El-Okl, M., Williams, A. L., 
Cunningham, C., Wilcockson, D., and 
Perry, V. H. (2003). Systemic infection, 
interleukin 1beta, and cognitive decline 
in Alzheimer’s disease. J. Neurol. 
Neurosurg. Psychiatr. 74, 788–789.
Hopkins, S. J., and Rothwell, N. J. (1995). 
Cytokines and the nervous system. I: 
Expression and recognition. Trends 
Neurosci 18, 83–88.
Hua, J. Y., and, Smith, S. J. (2004). Neural 
activity and the dynamics of central 
nervous system development. Nat. 
Neurosci. 7, 327–332.
Huh, G. S., Boulanger, L. M., Du, H., 
Riquelme, P. A., Brotz, T. M., and 
Shatz, C. J. (2000). Functional require-
ment for class I MHC in CNS devel-
opment and plasticity. Science 290, 
2155–2159.
Ibata, K., Sun, Q., and Turrigiano, G. G. 
(2008). Rapid synaptic scaling induced 
by changes in postsynaptic firing. 
Neuron 57, 819–826.
Inman, C. F., Haverson, K., Konstantinov, 
S. R., Jones, P. H., Harris, C., Smidt, H., 
Miller, B., Bailey, M., and Stokes, C. 
(2010). Rearing environment affects 
development of the immune system 
in neonates. Clin. Exp. Immunol. 76, 
696–704.
Ishii, T., and Mombaerts, P. (2008). 
Expression of nonclassical class I 
major histocompatibility genes defines 
a tripartite organization of the mouse 
vomeronasal system. J. Neurosci. 28, 
2332–2341.
Jaaro-Peled, H., Ayhan, Y., Pletnikov, M. V., 
and Sawa, A. (2007). Review of path-
ological hallmarks of schizophrenia: 
comparison of genetic models with 
patients and nongenetic models. 
Schizophr. Bull. 36, 301–313.
Janeway, C.,  Travers, P., Walport, M., and 
Shlomchik, M. (2005). Immunobiology: 
The Immune System in Health and 
Disease. New York: Garland Science 
Publishing.
Jankowsky, J. L., Derrick, B. E., and 
Patterson, P. H. (2000). Cytokine 
A. M. (2008). Immune transcriptome 
alterations in the temporal cortex of 
subjects with autism. Neurobiol. Dis. 
30, 303–311.
Garofalo, R. (2010). Cytokines in human 
milk. J. Pediatr. 156, S36–S40.
Garofalo, R. P., and Goldman, A. S. (1998). 
Cytokines, chemokines, and colony-
stimulating factors in human milk: 
the 1997 update. Biol. Neonate 74, 
134–142.
Gasque, P., Singhrao, S. K., Neal, J. W., 
Wang, P., Sayah, S., Fontaine, M., and 
Morgan, B. P. (1998). The receptor 
for complement anaphylatoxin C3a is 
expressed by myeloid cells and nonmy-
eloid cells in inflamed human central 
nervous system: analysis in multiple 
sclerosis and bacterial meningitis. J. 
Immunol. 160, 3543–3554.
Geppert, A. M. (2003). Constitutive pat-
terns of RANTES, MCP-1 and MIP-1 
alpha expression at the mRNA and 
protein level during postnatal 
development of the rat brain. Folia 
Neuropathol. 41, 79–88.
Gilmore, J. H., Jarskog, L. F., and 
Vadlamudi, S. (2005). Maternal poly 
I:C exposure during pregnancy regu-
lates TNF alpha, BDNF, and NGF 
expression in neonatal brain and 
the maternal-fetal unit of the rat. J. 
Neuroimmunol. 159, 106–112.
Goddard, C. A., Butts, D. A., and Shatz, C. 
J. (2007). Regulation of CNS synapses 
by neuronal MHC class I. Proc. Natl. 
Acad. Sci. U.S.A. 104, 6828–6833.
Goldman, A. S., Chheda, S., Garofalo, 
R., and Schmalstieg, F. C. (1996). 
Cytokines in human milk: proper-
ties and potential effects upon the 
mammary gland and the neonate. J. 
Mammary Gland Biol. Neoplasia 1, 
251–258.
Graber, J. J., and Dhib-Jalbut, S. (2009). 
Protective autoimmunity in the nerv-
ous system. Pharmacol. Ther. 121, 
147–159.
Hanninen, K., Katila, H., Saarela, M., 
Rontu, R., Mattila, K. M., Fan, M., 
Hurme, M., and Lehtimaki, T. (2008). 
Interleukin-1 beta gene polymorphism 
and its interactions with neuregulin-1 
gene polymorphism are associated with 
schizophrenia. Eur. Arch. Psychiatry 
Clin. Neurosci. 258, 10–15.
Harkness, K. A., Sussman, J. D., Davies-
Jones, G. A., Greenwood, J., and 
Woodroofe, M. N. (2003). Cytokine 
regulation of MCP-1 expression 
in brain and retinal microvascular 
endothelial cells. J. Neuroimmunol. 
142, 1–9.
Harnesk, K., Swanberg, M., Diez, M., 
Olsson, T., Piehl, F., and Lidman, O. 
(2009). Differential nerve injury-
 induced expression of MHC class II 
in the mouse correlates to genetic vari-
ability in the type I promoter of C2ta. 
J. Neuroimmunol. 212, 44–52.
Edstrom, E., Kullberg, S., Ming, Y., Zheng, 
H., and Ulfhake, B. (2004). MHC class 
I, beta2 microglobulin, and the INF-
gamma receptor are upregulated in 
aged motoneurons. J. Neurosci. Res. 
78, 892–900.
Enstrom, A. M., Lit, L., Onore, C. E., 
Gregg, J. P., Hansen, R. L., Pessah, I. N., 
Hertz-Picciotto, I., Van de Water, J. A., 
Sharp, F. R., and Ashwood, P. (2009). 
Altered gene expression and function 
of peripheral blood natural killer cells 
in children with autism. Brain Behav. 
Immun. 23, 124–133.
Fatemi, S. H., Halt, A. R., Realmuto, G., 
Earle, J., Kist, D. A., Thuras, P., and 
Merz, A. (2002). Purkinje cell size 
is reduced in cerebellum of patients 
with autism. Cell Mol. Neurobiol. 22, 
171–175.
Fatemi, S. H., Reutiman, T. J., Folsom, 
T. D., Huang, H., Oishi, K., Mori, S., 
Smee, D. F., Pearce, D. A., Winter, 
C., Sohr, R., and Juckel, G. (2008). 
Maternal infection leads to abnormal 
gene regulation and brain atrophy in 
mouse offspring: implications for gen-
esis of neurodevelopmental disorders. 
Schizophr. Res. 99, 56–70.
Feng, Z., and Ko, C. P. (2008). Schwann 
cells promote synaptogenesis at the 
neuromuscular junction via trans-
forming growth factor-beta1. J. 
Neurosci. 28, 9599–9609.
Fourgeaud, L., and Boulanger, L. M. 
(2007). Synapse remodeling, compli-
ments of the complement system. Cell 
131, 1034–1036.
Fujimaki, H., Hikawa, N., Nagoya, M., 
Nagata, T., and Minami, M. (1996). 
IFN-gamma induces expression 
of MHC class I molecules in adult 
mouse dorsal root ganglion neurones. 
Neuroreport 7, 2951–2955.
Fukushima, T., Liu, R. Y., and Byrne, J. H. 
(2007). Transforming growth factor-
beta2 modulates synaptic efficacy and 
plasticity and induces phosphoryla-
tion of CREB in hippocampal neu-
rons. Hippocampus 17, 5–9.
Gadient, R. A., and Otten, U. (1994). 
Expression of interleukin-6 (IL-6) 
and interleukin-6 receptor (IL-6R) 
mRNAs in rat brain during post-
natal development. Brain Res. 637, 
10–14.
Gainey, M. A., Hurvitz-Wolff, J. R., Lambo, 
M. E., and Turrigiano, G. G. (2009). 
Synaptic scaling requires the GluR2 
subunit of the AMPA receptor. J. 
Neurosci. 29, 6479–6489.
Galic, M. A., Riazi, K., Heida, J. G., 
Mouihate, A., Fournier, N. M., Spencer, 
S. J., Kalynchuk, L. E., Teskey, G. C., 
and Pittman, Q. J. (2008). Postnatal 
inflammation increases seizure sus-
ceptibility in adult rats. J. Neurosci. 
28, 6904–6913.
Garbett, K., Ebert, P. J., Mitchell, A., Lintas, 
C., Manzi, B., Mirnics, K., and Persico, 
Frontiers in Synaptic Neuroscience www.frontiersin.org September 2010 | Volume 2 | Article 136 | 15
Garay and McAllister Immune molecules in neural development
Ribic, A., Zhang, M., Schlumbohm, C., 
Mätz-Rensing, K., Uchanska-Ziegler, 
B., Flügge, G., Zhang, W., Walter, 
L., and Fuchs, E. (2010). Neuronal 
MHC Class I molecules are involved 
in excitatory synaptic transmission 
at the hippocampal mossy fiber syn-
apses of marmoset monkeys. Cell Mol. 
Neurobiol. 30, 827–839.
Rothman, A., Perry, S. B., Keane, J. F., and 
Lock, J. E. (1990). Early results and 
follow-up of balloon angioplasty for 
branch pulmonary artery stenoses. J. 
Am. Coll. Cardiol. 15, 1109–1117.
Rothwell, N. J., and Hopkins, S. J. (1995). 
Cytokines and the nervous system II: 
actions and mechanisms of action. 
Trends Neurosci. 18, 130–136.
Rothwell, N. J., Luheshi, G., and 
Toulmond, S. (1996). Cytokines and 
their receptors in the central nervous 
system: physiology, pharmacology, 
and pathology. Pharmacol. Ther. 69, 
85–95.
Roumier, A., Pascual, O., Bechade, C., 
Wakselman, S., Poncer, J. C., Real, 
E., Triller, A., and Bessis, A. (2008). 
Prenatal activation of microglia 
induces delayed impairment of 
glutamatergic synaptic function. PLoS 
One 3:e2595. doi:10.1371/journal.
pone.0002595.
Saetre, P., Emilsson, L., Axelsson, E., 
Kreuger, J., Lindholm, E., and Jazin, 
E. (2007). Inflammation-related genes 
up-regulated in schizophrenia brains. 
BMC Psychiatry 7, 46.
Sanyal, S., Kim, S. M., and Ramaswami, 
M. (2004). Retrograde regulation in 
the CNS; neuron-specific interpreta-
tions of TGF-beta signaling. Neuron 
41, 845–848.
Savin, C., Triesch, J., and Meyer-Hermann, 
M. (2009). Epileptogenesis due to glia-
mediated synaptic scaling. J. R. Soc. 
Interface 6, 655–668.
Schiefer, J., Kampe, K., Dodt, H. U., 
Zieglgansberger, W., and Kreutzberg, 
G. W. (1999). Microglial motility 
in the rat facial nucleus following 
peripheral axotomy. J. Neurocytol. 
28, 439–453.
Schmidt, R., Schmidt, H., Curb, J. D., 
Masaki, K., White, L. R., and Launer, 
L. J. (2002). Early inflammation and 
dementia: a 25-year follow-up of the 
Honolulu-Asia Aging Study. Ann. 
Neurol. 52, 168–174.
Shatz, C. J. (2009). MHC class I: an unex-
pected role in neuronal plasticity. 
Neuron 64, 40–45.
Shi, L., Fatemi, S. H., Sidwell, R. W., and 
Patterson, P. H. (2003). Maternal 
influenza infection causes marked 
behavioral and pharmacological 
changes in the offspring. J. Neurosci. 
23, 297–302.
Shi, J., Levinson, D. F., Duan, J., Sanders, 
A. R., Zheng, Y., Pe’er, I., Dudbridge, 
F., Holmans, P. A., Whittemore, A. 
ulate cerebellar functions. Mol. Cell. 
Biol. 27, 5128–5134.
Neumann, H., Schmidt, H., Cavalie, A., 
Jenne, D., and Wekerle, H. (1997). 
Major histocompatibility complex 
(MHC) class I gene expression in 
single neurons of the central nerv-
ous system: differential regulation by 
interferon (IFN)-gamma and tumor 
necrosis factor (TNF)-alpha. J. Exp. 
Med. 185, 305–316.
Oliveira, A. L., Thams, S., Lidman, O., 
Piehl, F., Hokfelt, T., Karre, K., Linda, 
H., and Cullheim, S. (2004). A role for 
MHC class I molecules in synaptic 
plasticity and regeneration of neu-
rons after axotomy. Proc. Natl. Acad. 
Sci. U.S.A. 101, 17843–17848.
Oliver, K. R., Scallan, M. F., Dyson, H., and 
Fazakerley, J. K. (1997). Susceptibility 
to a neurotropic virus and its chang-
ing distribution in the developing 
brain is a function of CNS maturity. 
J. Neurovirol. 3, 38–48.
Pacheco, R., Ciruela, F., Casado, V., Mallol, 
J., Gallart, T., Lluis, C., and Franco, R. 
(2004). Group I metabotropic gluta-
mate receptors mediate a dual role of 
glutamate in T cell activation. J. Biol. 
Chem. 279, 33352–33358.
Pardo, C. A., Vargas, D. L., and Zimmerman, 
A. W. (2005). Immunity, neuroglia and 
neuroinflammation in autism. Int. 
Rev. Psychiatry 17, 485–495.
Patterson, P. H. (2002). Maternal infec-
tion: window on neuroimmune inter-
actions in fetal brain development and 
mental illness. Curr. Opin. Neurobiol. 
12, 115–118.
Patterson, P. H. (2009). Immune involve-
ment in schizophrenia and autism: eti-
ology, pathology and animal models. 
Behav. Brain Res. 204, 313–321.
Pavlowsky, A., Gianfelice, A., Pallotto, 
M., Zanchi, A., Vara, H., Khelfaoui, 
M., Valnegri, P., Rezai, X., Bassani, S., 
Brambilla, D., Kumpost, J., Blahos, J., 
Roux, M. J., Humeau, Y., Chelly, J., 
Passafaro, M., Giustetto, M., Billuart, 
P., and Sala, C. (2010). A postsynaptic 
signaling pathway that may account for 
the cognitive defect due to IL1RAPL1 
mutation. Curr. Biol. 20, 103–115. 
Perry, V. H., and O’Connor, V. (2008). 
C1q: the perfect complement for a 
synaptic feast? Nat. Rev. Neurosci. 9, 
807–811.
Piontkewitz, Y. Assaf ,Y., and Weiner, 
I. (2007). Post-pubertal emergence 
of schizophrenia like abnormali-
ties following prenatal maternal 
immunesystem activation and their 
prevention: modeling the disorder 
and its prodrome. Int. Brain Res. 
Org. 7, 25–33.
Pousset, F. (1994). Developmental expres-
sion of cytokine genes in the cortex 
and hippocampus of the rat central 
nervous system. Brain Res. Dev. Brain 
Res. 81, 143–146.
 expression of MHC class I antigens in 
rat motor neurons and skeletal mus-
cles. Brain Res. 481, 368–372.
Mak, T. K., Mangtani, P., Leese, J., Watson, 
J. M., and Pfeifer, D. (2008). Influenza 
vaccination in pregnancy: current evi-
dence and selected national policies. 
Lancet. Infect. Dis. 8, 44–52.
McAllister, A. K., and van de Water, 
J. (2009). Breaking boundaries in 
neural-immune interactions. Neuron 
64, 9–12.
McConnell, M. J., Huang, Y. H., Datwani, 
A., and Shatz, C. J. (2009). H2-K(b) 
and H2-D(b) regulate cerebellar 
long-term depression and limit motor 
learning. Proc. Natl. Acad. Sci. U.S.A. 
106, 6784–6789.
Mednick, S. A., Machon, R. A., Huttunen, 
M. O., and Bonett, D. (1988). Adult 
schizophrenia following prenatal 
exposure to an influenza epidemic. 
Arch. Gen. Psychiatry 45, 189–192.
Mehler, M. F., and Kessler, J. A. (1995). 
Cytokines and neuronal differentia-
tion. Crit. Rev. Neurobiol. 9, 419–446.
Mendoza-Fernandez, V., Andrew, R. 
D., and Barajas-Lopez, C. (2000). 
Interferon-alpha inhibits long-term 
potentiation and unmasks a long-term 
depression in the rat hippocampus. 
Brain Res. 885, 14–24.
Meng, S. Z., Oka, A., and Takashima, S. 
(1999). Developmental expression of 
monocyte chemoattractant protein-1 
in the human cerebellum and brain-
stem. Brain Dev. 21, 30–35.
Meyer, U., Nyffeler, M., Engler, A., Urwyler, 
A., Schedlowski, M., Knuesel, I., Yee, 
B. K., and Feldon, J. (2006). The time 
of prenatal immune challenge deter-
mines the specificity of inflammation-
 mediated brain and behavioral 
pathology. J. Neurosci. 26, 4752–4762.
Meyer, U., Nyffeler, M., Schwendener, 
S., Knuesel, I., Yee, B. K., and Feldon, 
J. (2008a). Relative prenatal and 
postnatal maternal contributions to 
schizophrenia-related neurochemical 
dysfunction after in utero immune 
challenge. Neuropsychopharmacology 
33, 441–456.
Meyer, U., Nyffeler, M., Yee, B. K., Knuesel, 
I., and Feldon, J. (2008b). Adult brain 
and behavioral pathological markers 
of prenatal immune challenge during 
early/middle and late fetal develop-
ment in mice. Brain Behav. Immun. 
22, 469–486.
Monji, A., Kato, T., and Kanba, S. (2009). 
Cytokines and schizophrenia: 
microglia hypothesis of schizophre-
nia. Psychiatry Clin. Neurosci. 63, 
257–265.
Nakamura, K., Hirai, H., Torashima, 
T., Miyazaki, T., Tsurui, H., Xiu, Y., 
Ohtsuji, M., Lin, Q. S., Tsukamoto, 
K., Nishimura, H., Ono, M., Watanabe, 
M., and Hirose, S. (2007). CD3 and 
immunoglobulin G Fc receptor reg-
modulation of N-cadherin expression. 
J. Neurochem. 110, 496–508.
Lavi, E., Suzumura, A., Murasko, D. M., 
Murray, E. M., Silberberg, D. H., and 
Weiss, S. R. (1988). Tumor necrosis 
factor induces expression of MHC 
class I antigens on mouse astrocytes. 
J. Neuroimmunol. 18, 245–253.
Lee, R. H., Mills, E. A., Schwartz, N., Bell, 
M. R., Deeg, K. E., Ruthazer, E. S., 
Marsh-Armstrong, N., and Aizenman, 
C. D. (2010). Neurodevelopmental 
effects of chronic exposure to elevated 
levels of pro-inflammatory cytokine 
in a developing visual system. Neural 
Dev. 5, 2.
Letellier, M., Willson, M. L., Gautheron, 
V., Mariani, J., and Lohof, A. M. 
(2008). Normal adult climbing 
fiber monoinnervation of cerebellar 
Purkinje cells in mice lacking MHC 
class I molecules. Dev. Neurobiol. 68, 
997–1006.
Li, A. J., Katafuchi, T., Oda, S., Hori, T., 
and Oomura, Y. (1997). Interleukin-6 
inhibits long-term potentiation in rat 
hippocampal slices. Brain Res. 748, 
30–38.
Lidman, O., Olsson, T., and Piehl, F. 
(1999). Expression of nonclassi-
cal MHC class I (RT1-U) in certain 
neuronal populations of the central 
nervous system. Eur. J. Neurosci. 11, 
4468–4472.
Lin, Y., Bloodgood, B. L., Hauser, J. L., 
Lapan, A. D., Koon, A. C., Kim, T. K., 
Hu, L. S., Malik, A. N., and Greenberg, 
M. E. (2008). Activity-dependent 
regulation of inhibitory synapse 
development by Npas4. Nature 455, 
1198–1204.
Linda, H., Hammarberg, H., Cullheim, 
S., Levinovitz, A., Khademi, M., and 
Olsson, T. (1998). Expression of MHC 
class I and beta2-microglobulin in rat 
spinal motoneurons: regulatory influ-
ences by IFN-gamma and axotomy. 
Exp. Neurol. 150, 282–295.
Loconto, J., Papes, F., Chang, E., Stowers, 
L., Jones, E. P., Takada, T., Kumanovics, 
A., Fischer Lindahl, K., and Dulac, 
C. (2003). Functional expression of 
murine V2R pheromone receptors 
involves selective association with the 
M10 and M1 families of MHC class Ib 
molecules. Cell 112, 607–618.
Long, E. O. (2008). Negative signaling by 
inhibitory receptors: the NK cell para-
digm. Immunol. Rev. 224, 70–84.
Machold, R. P., and Ploegh, H. L. (1996). 
Intermediates in the assembly and 
degradation of class I major histocom-
patibility complex (MHC) molecules 
probed with free heavy chain-specific 
monoclonal antibodies. J. Exp. Med. 
184, 2251–2259.
Maehlen, J., Nennesmo, I., Olsson, A. 
B., Olsson, T., Daa Schroder, H., and 
Kristensson, K. (1989). Peripheral 
nerve injury causes transient 
Frontiers in Synaptic Neuroscience www.frontiersin.org September 2010 | Volume 2 | Article 136 | 16
Garay and McAllister Immune molecules in neural development
circuits in the retina. Neuron 65, 
503–515.
Yamada, S., and Nelson, W. J. (2007). 
Synapses: sites of cell recognition, 
adhesion, and functional speci-
fication. Annu. Rev. Biochem. 76, 
267–294.
Yang, S., Liu, Z. W., Wen, L., Qiao, H. F., 
Zhou, W. X., and Zhang, Y. X. (2005). 
Interleukin-1beta enhances NMDA 
receptor-mediated current but inhib-
its excitatory synaptic transmission. 
Brain Res. 1034, 172–179.
Yee, B. K., Keist, R., von Boehmer, L., 
Studer, R., Benke, D., Hagenbuch, 
N., Dong, Y., Malenka, R. C., Fritschy, 
J. M., Bluethmann, H., Feldon, J., 
Mohler, H., and Rudolph, U. (2005). 
A schizophrenia-related sensorimo-
tor deficit links alpha 3-containing 
GABAA receptors to a dopamine 
hyperfunction. Proc. Natl. Acad. Sci. 
U.S.A. 102, 17154–17159.
Zeise, M. L., Madamba, S., and Siggins, G. 
R. (1992). Interleukin-1 beta increases 
synaptic inhibition in rat hippocam-
pal pyramidal neurons in vitro. Regul. 
Pept. 39, 1–7.
Zhao, B., and Schwartz, J. P. (1998). 
Involvement of cytokines in nor-
mal CNS development and neuro-
logical diseases: recent progress and 
 perspectives. J. Neurosci. Res. 52, 
7–16.
Zhou, F. (2009). Molecular mechanisms of 
IFN-gamma to up-regulate MHC class 
I antigen processing and presentation. 
Int. Rev. Immunol. 28, 239–260.
Zohar, O., Reiter, Y., Bennink, J. R., Lev, A., 
Cavallaro, S., Paratore, S., Pick, C. G., 
Brooker, G., and Yewdell, J. W. (2008). 
Cutting edge: MHC class I-Ly49 inter-
action regulates neuronal function. J. 
Immunol. 180, 6447–6451.
Conflict of Interest Statement: The 
authors declare that the research was con-
ducted in the absence of any commercial or 
financial relationships that could be con-
strued as a potential conflict of interest.
Received: 26 March 2010; paper pend-
ing published: 04 May 2010; accepted: 
03 August 2010; published online: 08 
September 2010.
Citation: Garay PA and McAllister AK 
(2010) Novel roles for immune mol-
ecules in neural development: implica-
tions for neurodevelopmental disorders. 
Front. Syn. Neurosci. 2:136. doi: 10.3389/
fnsyn.2010.00136
Copyright © 2010 Garay and McAllister. 
This is an open-access article subject to 
an exclusive license agreement between 
the authors and the Frontiers Research 
Foundation, which permits unrestricted 
use, distribution, and reproduction in any 
medium, provided the original authors 
and source are credited.
Tancredi, V., D’Arcangelo, G., Grassi, F., 
Tarroni, P., Palmieri, G., Santoni, A., 
and Eusebi, F. (1992). Tumor necrosis 
factor alters synaptic transmission in 
rat hippocampal slices. Neurosci. Lett. 
146, 176–178.
Tancredi, V., Zona, C., Velotti, F., Eusebi, F., 
and Santoni, A. (1990). Interleukin-2 
suppresses established long-term 
potentiation and inhibits its induc-
tion in the rat hippocampus. Brain 
Res. 525, 149–151.
Tian, J., Chau, C., Hales, T. G., and 
Kaufman, D. L. (1999). GABA(A) 
receptors mediate inhibition of T 
cell responses. J. Neuroimmunol. 96, 
21–28.
Turrigiano, G. G. (2008). The self-tuning 
neuron: synaptic scaling of excitatory 
synapses. Cell 135, 422–435.
Vargas, D. L., Nascimbene, C., Krishnan, 
C., Zimmerman, A. W., and Pardo, C. 
A. (2005). Neuroglial activation and 
neuroinflammation in the brain of 
patients with autism. Ann. Neurol. 
57, 67–81.
Vezzani, A., Balosso, S., and Ravizza, T. 
(2008). The role of cytokines in the 
pathophysiology of epilepsy. Brain 
Behav. Immun. 22, 797–803.
Vikman, K., Robertson, B., Grant, G., 
Liljeborg, A., and Kristensson, K. 
(1998). Interferon-gamma recep-
tors are expressed at synapses in the 
rat superficial dorsal horn and lat-
eral spinal nucleus. J. Neurocytol. 27, 
749–759.
Wallace, J. M., Ferguson, S. J., Loane, P., 
Kell, M., Millar, S., and Gillmore, W. 
S. (1997). Cytokines in human breast 
milk. Br. J. Biomed. Sci. 54, 85–87.
Wang, S., Cheng, Q., Malik, S., and 
Yang, J. (2000). Interleukin-1beta 
inhibits gamma-aminobutyric acid 
type A (GABA(A)) receptor cur-
rent in cultured hippocampal neu-
rons. J. Pharmacol. Exp. Ther. 292, 
497–504.
Warren, R. P., Odell, J. D., Warren, W. L., 
Burger, R. A., Maciulis, A., Daniels, 
W. W., and Torres, A. R. (1996). 
Strong association of the third 
 hypervariable region of HLA-DR 
beta 1 with autism. J. Neuroimmunol. 
67, 97–102.
Xiong, H., Boyle, J., Winkelbauer, M., 
Gorantla, S., Zheng, J., Ghorpade, 
A., Persidsky, Y., Carlson, K. A., 
and Gendelman, H. E. (2003). 
Inhibition of long-term potentia-
tion by interleukin-8: implications 
for human immunodeficiency virus-
1- associated dementia. J. Neurosci. 
Res. 71, 600–607.
Xu, H. P., Chen, H., Ding, Q., Xie, Z. H., 
Chen, L., Diao, L., Wang, P., Gan, L., 
Crair, M. C., and Tian, N. (2010). The 
immune protein CD3zeta is required 
for normal development of  neural 
S., Mattheisen, M., Bitter, I., Rethelyi, J. 
M., Magnusdottir, B. B., Sigmundsson, 
T., Olason, P., Masson, G., Gulcher, 
J. R., Haraldsson, M., Fossdal, R., 
Thorgeirsson, T. E., Thorsteinsdottir, 
U., Ruggeri, M., Tosato, S., Franke, 
B., Strengman, E., Kiemeney, L. A., 
Melle, I., Djurovic, S., Abramova, 
L., Kaleda, V., Sanjuan, J., de Frutos, 
R., Bramon, E., Vassos, E., Fraser, G., 
Ettinger, U., Picchioni, M., Walker, N., 
Toulopoulou, T., Need, A. C., Ge, D., 
Yoon, J. L., Shianna, K. V., Freimer, N. 
B., Cantor, R. M., Murray, R., Kong, A., 
Golimbet, V., Carracedo, A., Arango, 
C., Costas, J., Jonsson, E. G., Terenius, 
L., Agartz, I., Petursson, H., Nothen, 
M. M., Rietschel, M., Matthews, P. M., 
Muglia, P., Peltonen, L., St Clair, D., 
Goldstein, D. B., Stefansson, K., and 
Collier, D. A. (2009). Common vari-
ants conferring risk of schizophrenia. 
Nature 460, 744–747.
Stellwagen, D., Beattie, E. C., Seo, J. Y., and 
Malenka, R. C. (2005). Differential 
regulation of AMPA receptor and 
GABA receptor trafficking by tumor 
necrosis factor-alpha. J. Neurosci. 25, 
3219–3228.
Stellwagen, D., and Malenka, R. C. (2006). 
Synaptic scaling mediated by glial 
TNF-alpha. Nature 440, 1054–1059.
Stevens, B., Allen, N. J., Vazquez, L. E., 
Howell, G. R., Christopherson, K. S., 
Nouri, N., Micheva, K. D., Mehalow, 
A. K., Huberman, A. D., Stafford, B., 
Sher, A., Litke, A. M., Lambris, J. D., 
Smith, S. J., John, S. W., and Barres, B. 
A. (2007). The classical complement 
cascade mediates CNS synapse elimi-
nation. Cell 131, 1164–1178.
Suzuki, K., Kumanogoh, A., and Kikutani, 
H. (2008). Semaphorins and their 
receptors in immune cell interactions. 
Nat. Immunol. 9, 17–23.
Syken, J., Grandpre, T., Kanold, P. O., 
and Shatz, C. J. (2006). PirB restricts 
ocular-dominance plasticity in visual 
cortex. Science 313, 1795–1800.
Syken, J., and Shatz, C. J. (2003). Expression 
of T cell receptor beta locus in central 
nervous system neurons. Proc. Natl. 
Acad. Sci. U.S.A. 100, 13048–13053.
Takao, T., Culp, S. G., Newton, R. C., 
and De Souza, E. B. (1992). Type I 
interleukin-1 receptors in the mouse 
brain-endocrine-immune axis labelled 
with [125I]recombinant human 
interleukin-1 receptor antagonist. J. 
Neuroimmunol. 41, 51–60.
Tancredi, V., D’Antuono, M., Cafe, C., 
Giovedi, S., Bue, M. C., D’Arcangelo, 
G., Onofri, F., and Benfenati, F. (2000). 
The inhibitory effects of interleukin-6 
on synaptic plasticity in the rat hip-
pocampus are associated with an 
inhibition of mitogen-activated pro-
tein kinase ERK. J. Neurochem. 75, 
634–643.
S., Mowry, B. J., Olincy, A., Amin, 
F., Cloninger, C. R., Silverman, J. M., 
Buccola, N. G., Byerley, W. F., Black, 
D. W., Crowe, R. R., Oksenberg, J. R., 
Mirel, D. B., Kendler, K. S., Freedman, 
R., and Gejman, P. V. (2009a). Common 
variants on chromosome 6p22.1 are 
associated with schizophrenia. Nature 
460, 753–757.
Shi, L., Smith, S. E., Malkova, N., Tse, D., 
Su, Y., and Patterson, P. H. (2009b). 
Activation of the maternal immune 
system alters cerebellar development 
in the offspring. Brain Behav. Immun. 
23, 116–123.
Shi, L., Tu, N., and Patterson, P. H. (2005). 
Maternal influenza infection is likely 
to alter fetal brain development 
indirectly: the virus is not detected 
in the fetus. Int. J. Dev. Neurosci. 23, 
299–305.
Short, S. J., Lubach, G. R., Karasin, A. I., 
Olsen, C. W., Styner, M., Knickmeyer, 
R. C., Gilmore, J. H., and Coe, C. L. 
(2010). Maternal influenza infection 
during pregnancy impacts postnatal 
brain development in the Rhesus mon-
key. Biol Psychiatry. 67, 965–973.
Smith, S. E., Li, J., Garbett, K., Mirnics, K., 
and Patterson, P. H. (2007). Maternal 
immune activation alters fetal brain 
development through interleukin-6. 
J. Neurosci. 27, 10695–10702.
Sourial-Bassillious, N., Eklof, A. C., Scott, 
L., Aperia, A., and Zelenin, S. (2006). 
Effect of TNF-alpha on CD3-zeta and 
MHC-I in postnatal rat hippocampus. 
Pediatr. Res. 60, 377–381.
Sozzani, S., Bosisio, D., Scarsi, M., and 
Tincani, A. (2010). Type I inter-
ferons in systemic autoimmunity. 
Autoimmunity 43, 196–203.
Sperner-Unterweger, B. (2005). 
Immunological aetiology of major 
psychiatric disorders: evidence and 
therapeutic implications. Drugs 65, 
1493–1520.
Spulber, S., Bartfai, T., and Schultzberg, 
M. (2009). IL-1/IL-1ra balance in the 
brain revisited – evidence from trans-
genic mouse models. Brain Behav. 
Immun. 23, 573–579.
Srivastava, M. D., Srivastava, A., Brouhard, 
B., Saneto, R., Groh-Wargo, S., and 
Kubit, J. (1996). Cytokines in human 
milk. Res. Commun. Mol. Pathol. 
Pharmacol. 93, 263–287.
Stefansson, H., Ophoff, R. A., Steinberg, S., 
Andreassen, O. A., Cichon, S., Rujescu, 
D., Werge, T., Pietilainen, O. P., Mors, 
O., Mortensen, P. B., Sigurdsson, E., 
Gustafsson, O., Nyegaard, M., Tuulio-
Henriksson, A., Ingason, A., Hansen, 
T., Suvisaari, J., Lonnqvist, J., Paunio, 
T., Borglum, A. D., Hartmann, A., Fink-
Jensen, A., Nordentoft, M., Hougaard, 
D., Norgaard-Pedersen, B., Bottcher, 
Y., Olesen, J., Breuer, R., Moller, H. J., 
Giegling, I., Rasmussen, H. B., Timm, 
